Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?


Cite item

Full Text

Abstract

Parkinsonian disorders are a heterogeneous group of incurable neurodegenerative diseases that significantly reduce quality of life and constitute a substantial economic burden. Nuclear imaging (NI) and magnetic resonance imaging (MRI) have played and continue to play a key role in research aimed at understanding and monitoring these disorders. MRI is cheaper, more accessible, nonirradiating, and better at measuring biological structures and hemodynamics than NI. NI, on the other hand, can track molecular processes, which may be crucial for the development of efficient diseasemodifying therapies. Given the strengths and weaknesses of NI and MRI, how can they best be applied to Parkinsonism research going forward? This review aims to examine the effectiveness of NI and MRI in three areas of Parkinsonism research (differential diagnosis, prodromal disease identification, and disease monitoring) to highlight where they can be most impactful. Based on the available literature, MRI can assist with differential diagnosis, prodromal disease identification, and disease monitoring as well as NI. However, more work is needed, to confirm the value of MRI for monitoring prodromal disease and predicting phenoconversion. Although NI can complement or be a substitute for MRI in all the areas covered in this review, we believe that its most meaningful impact will emerge once reliable Parkinsonian proteinopathy tracers become available. Future work in tracer development and high-field imaging will continue to influence the landscape for NI and MRI.

About the authors

Félix-Antoine Savoie

Department of Applied Physiology and Kinesiology, Laboratory for Rehabilitation Neuroscience,, University of Florida,

Email: info@benthamscience.net

David Arpin

Department of Applied Physiology and Kinesiology, Laboratory for Rehabilitation Neuroscience, University of Florida

Email: info@benthamscience.net

David Vaillancourt

Department of Applied Physiology and Kinesiology, Laboratory for Rehabilitation Neuroscience,, University of Florida

Author for correspondence.
Email: info@benthamscience.net

References

  1. Bloem, B.R.; Okun, M.S.; Klein, C. Parkinson’s disease. Lancet, 2021, 397(10291), 2284-2303. doi: 10.1016/S0140-6736(21)00218-X PMID: 33848468
  2. Ahmed, Z.; Asi, Y.T.; Sailer, A.; Lees, A.J.; Houlden, H.; Revesz, T.; Holton, J.L. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol., 2012, 38(1), 4-24. doi: 10.1111/j.1365-2990.2011.01234.x PMID: 22074330
  3. Dickson, D.W.; Ahmed, Z.; Algom, A.A.; Tsuboi, Y.; Josephs, K.A. Neuropathology of variants of progressive supranuclear palsy. Curr. Opin. Neurol., 2010, 23(4), 394-400. doi: 10.1097/WCO.0b013e32833be924 PMID: 20610990
  4. Dickson, D.W.; Bergeron, C.; Chin, S.S.; Duyckaerts, C.; Horoupian, D.; Ikeda, K.; Jellinger, K.; Lantos, P.L.; Lippa, C.F.; Mirra, S.S.; Tabaton, M.; Vonsattel, J.P.; Wakabayashi, K.; Litvan, I. Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J. Neuropathol. Exp. Neurol., 2002, 61(11), 935-946. doi: 10.1093/jnen/61.11.935 PMID: 12430710
  5. Fearnley, J.M.; Lees, A.J. Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain, 1991, 114(5), 2283-2301. doi: 10.1093/brain/114.5.2283 PMID: 1933245
  6. Oyanagi, K.; Tsuchiya, K.; Yamazaki, M.; Ikeda, K. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: Specific pathological features. J. Neuropathol. Exp. Neurol., 2001, 60(4), 393-402. doi: 10.1093/jnen/60.4.393 PMID: 11305875
  7. Ozawa, T.; Paviour, D.; Quinn, N.P.; Josephs, K.A.; Sangha, H.; Kilford, L.; Healy, D.G.; Wood, N.W.; Lees, A.J.; Holton, J.L.; Revesz, T. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: Clinicopathological correlations. Brain, 2004, 127(12), 2657-2671. doi: 10.1093/brain/awh303 PMID: 15509623
  8. Kordower, J.H.; Olanow, C.W.; Dodiya, H.B.; Chu, Y.; Beach, T.G.; Adler, C.H.; Halliday, G.M.; Bartus, R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain, 2013, 136(8), 2419-2431. doi: 10.1093/brain/awt192 PMID: 23884810
  9. Piggott, M.A.; Marshall, E.F.; Thomas, N.; Lloyd, S.; Court, J.A.; Jaros, E.; Burn, D.; Johnson, M.; Perry, R.H.; McKeith, I.G.; Ballard, C.; Perry, E.K. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: Rostrocaudal distribution. Brain, 1999, 122(8), 1449-1468. doi: 10.1093/brain/122.8.1449 PMID: 10430831
  10. Thomas, A.J.; Attems, J.; Colloby, S.J.; O’Brien, J.T.; McKeith, I.; Walker, R.; Lee, L.; Burn, D.; Lett, D.J.; Walker, Z. Autopsy validation of 123 I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology, 2017, 88(3), 276-283. doi: 10.1212/WNL.0000000000003512 PMID: 27940650
  11. Saeed, U.; Lang, A.E.; Masellis, M. Neuroimaging advances in Parkinson’s Disease and atypical parkinsonian syndromes. Front. Neurol., 2020, 11, 572976. doi: 10.3389/fneur.2020.572976 PMID: 33178113
  12. Roncevic, D.; Palma, J.A.; Martinez, J.; Goulding, N.; Norcliffe-Kaufmann, L.; Kaufmann, H. Cerebellar and parkinsonian phenotypes in multiple system atrophy: Similarities, differences and survival. J. Neural Transm. (Vienna), 2014, 121(5), 507-512. doi: 10.1007/s00702-013-1133-7 PMID: 24337696
  13. Williams, D.R.; de Silva, R.; Paviour, D.C.; Pittman, A.; Watt, H.C.; Kilford, L.; Holton, J.L.; Revesz, T.; Lees, A.J. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain, 2005, 128(6), 1247-1258. doi: 10.1093/brain/awh488 PMID: 15788542
  14. Deuschl, G.; Beghi, E.; Fazekas, F.; Varga, T.; Christoforidi, K.A.; Sipido, E.; Bassetti, C.L.; Vos, T.; Feigin, V.L. The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017. Lancet Public Health, 2020, 5(10), e551-e567. doi: 10.1016/S2468-2667(20)30190-0 PMID: 33007212
  15. Savica, R.; Grossardt, B.R.; Bower, J.H.; Boeve, B.F.; Ahlskog, J.E.; Rocca, W.A. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol., 2013, 70(11), 1396-1402. doi: 10.1001/jamaneurol.2013.3579 PMID: 24042491
  16. Tysnes, O.B.; Storstein, A. Epidemiology of Parkinson’s disease. J. Neural Transm. (Vienna), 2017, 124(8), 901-905. doi: 10.1007/s00702-017-1686-y PMID: 28150045
  17. Winter, Y.; Bezdolnyy, Y.; Katunina, E.; Avakjan, G.; Reese, J.P.; Klotsche, J.; Oertel, W.H.; Dodel, R.; Gusev, E. Incidence of Parkinson’s disease and atypical parkinsonism: Russian population-based study. Mov. Disord., 2010, 25(3), 349-356. doi: 10.1002/mds.22966 PMID: 20108378
  18. Bower, J.H.; Maraganore, D.M.; McDonnell, S.K.; Rocca, W.A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology, 1997, 49(5), 1284-1288. doi: 10.1212/WNL.49.5.1284 PMID: 9371909
  19. Mahapatra, R.K.; Edwards, M.J.; Schott, J.M.; Bhatia, K.P. Corticobasal degeneration. Lancet Neurol., 2004, 3(12), 736-743. doi: 10.1016/S1474-4422(04)00936-6 PMID: 15556806
  20. Schrag, A.; Wenning, G.K.; Quinn, N.; Ben-Shlomo, Y. Survival in multiple system atrophy. Mov. Disord., 2008, 23(2), 294-296. doi: 10.1002/mds.21839 PMID: 18044727
  21. Xie, T.; Yuen, C.A.; Kang, W.; Padmanaban, M.; Hain, T.C.; Nichols, J. Severity of downgaze palsy in the context of disease duration could estimate survival duration in patients with progressive supranuclear palsy. Front. Neurol., 2021, 12, 736784. doi: 10.3389/fneur.2021.736784 PMID: 34650511
  22. Wenning, G.K.; Litvan, I.; Jankovic, J.; Granata, R.; Mangone, C.A.; McKee, A.; Poewe, W.; Jellinger, K.; Chaudhuri, K.R.; D’Olhaberriague, L.; Pearce, R.K.B. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J. Neurol. Neurosurg. Psychiatry, 1998, 64(2), 184-189. doi: 10.1136/jnnp.64.2.184 PMID: 9489528
  23. Coyle-Gilchrist, I.T.S.; Dick, K.M.; Patterson, K.; Vázquez Rodríquez, P.; Wehmann, E.; Wilcox, A.; Lansdall, C.J.; Dawson, K.E.; Wiggins, J.; Mead, S.; Brayne, C.; Rowe, J.B. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology, 2016, 86(18), 1736-1743. doi: 10.1212/WNL.0000000000002638 PMID: 27037234
  24. Goetz, C.G.; Tilley, B.C.; Shaftman, S.R.; Stebbins, G.T.; Fahn, S.; Martinez-Martin, P.; Poewe, W.; Sampaio, C.; Stern, M.B.; Dodel, R.; Dubois, B.; Holloway, R.; Jankovic, J.; Kulisevsky, J.; Lang, A.E.; Lees, A.; Leurgans, S.; LeWitt, P.A.; Nyenhuis, D.; Olanow, C.W.; Rascol, O.; Schrag, A.; Teresi, J.A.; van Hilten, J.J.; LaPelle, N. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov. Disord., 2008, 23(15), 2129-2170. doi: 10.1002/mds.22340 PMID: 19025984
  25. Wenning, G.K.; Tison, F.; Seppi, K.; Sampaio, C.; Diem, A.; Yekhlef, F.; Ghorayeb, I.; Ory, F.; Galitzky, M.; Scaravilli, T.; Bozi, M.; Colosimo, C.; Gilman, S.; Shults, C.W.; Quinn, N.P.; Rascol, O.; Poewe, W. Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord., 2004, 19(12), 1391-1402. doi: 10.1002/mds.20255 PMID: 15452868
  26. Golbe, L.I.; Ohman-Strickland, P.A. A clinical rating scale for progressive supranuclear palsy. Brain, 2007, 130(6), 1552-1565. doi: 10.1093/brain/awm032 PMID: 17405767
  27. Grötsch, M.T.; Respondek, G.; Colosimo, C.; Compta, Y.; Corvol, J.C.; Ferreira, J.; Huber, M.K.; Klietz, M.; Krey, L.F.M.; Levin, J.; Jecmenica-Lukic, M.; Macías-García, D.; Meissner, W.G.; Mir, P.; Morris, H.; Nilsson, C.; Rowe, J.B.; Seppi, K.; Stamelou, M.; Swieten, J.C.; Wenning, G.; Del Ser, T.; Golbe, L.I.; Höglinger, G.U. Describe PSP Study Group. the ProPSP Study Group, and the Movement Disorder Society-Endorsed PSP Study Group. A modified progressive supranuclear palsy rating scale. Mov. Disord., 2021, 36(5), 1203-1215. doi: 10.1002/mds.28470 PMID: 33513292
  28. Lang, A.E.; Stebbins, G.T.; Wang, P.; Jabbari, E.; Lamb, R.; Morris, H.; Boxer, A.L. PROSPECT-M-UK investigators. The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism Relat. Disord., 2020, 79, 121-126. doi: 10.1016/j.parkreldis.2020.08.021 PMID: 32947108
  29. Chougar, L.; Pyatigorskaya, N.; Degos, B.; Grabli, D.; Lehéricy, S. The role of magnetic resonance imaging for the diagnosis of atypical parkinsonism. Front. Neurol., 2020, 11, 665. doi: 10.3389/fneur.2020.00665 PMID: 32765399
  30. Strafella, A.P.; Bohnen, N.I.; Pavese, N.; Vaillancourt, D.E.; Eimeren, T.; Politis, M.; Tessitore, A.; Ghadery, C.; Lewis, S. IPMDS‐Neuroimaging Study Group. Imaging Markers of Progression in Parkinson’s Disease. Mov. Disord. Clin. Pract. (Hoboken), 2018, 5(6), 586-596. doi: 10.1002/mdc3.12673 PMID: 30637278
  31. Yang, J.; Burciu, R.G.; Vaillancourt, D.E. Longitudinal progression markers of Parkinson’s Disease: Current view on structural imaging. Curr. Neurol. Neurosci. Rep., 2018, 18(12), 83. doi: 10.1007/s11910-018-0894-7 PMID: 30280267
  32. Lehericy, S.; Vaillancourt, D.E.; Seppi, K.; Monchi, O.; Rektorova, I.; Antonini, A.; McKeown, M.J.; Masellis, M.; Berg, D.; Rowe, J.B.; Lewis, S.J.G.; Williams-Gray, C.H.; Tessitore, A.; Siebner, H.R.; International, P. International Parkinson and Movement Disorder Society (IPMDS)-Neuroimaging Study Group. The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Mov. Disord., 2017, 32(4), 510-525. doi: 10.1002/mds.26968 PMID: 28370449
  33. Mitchell, T.; Lehéricy, S.; Chiu, S.Y.; Strafella, A.P.; Stoessl, A.J.; Vaillancourt, D.E. Emerging neuroimaging biomarkers across disease stage in Parkinson Disease. JAMA Neurol., 2021, 78(10), 1262-1272. doi: 10.1001/jamaneurol.2021.1312 PMID: 34459865
  34. Vaquero, J.J.; Kinahan, P. Positron emission tomography: Current challenges and opportunities for technological advances in clinical and preclinical imaging systems. Annu. Rev. Biomed. Eng., 2015, 17(1), 385-414. doi: 10.1146/annurev-bioeng-071114-040723 PMID: 26643024
  35. Accorsi, R. Brain single-photon emission CT physics principles. AJNR Am. J. Neuroradiol., 2008, 29(7), 1247-1256. doi: 10.3174/ajnr.A1175 PMID: 18583408
  36. Gilman, S.; Wenning, G.K.; Low, P.A.; Brooks, D.J.; Mathias, C.J.; Trojanowski, J.Q.; Wood, N.W.; Colosimo, C.; Dürr, A.; Fowler, C.J.; Kaufmann, H.; Klockgether, T.; Lees, A.; Poewe, W.; Quinn, N.; Revesz, T.; Robertson, D.; Sandroni, P.; Seppi, K.; Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 2008, 71(9), 670-676. doi: 10.1212/01.wnl.0000324625.00404.15 PMID: 18725592
  37. Höglinger, G.U.; Respondek, G.; Stamelou, M.; Kurz, C.; Josephs, K.A.; Lang, A.E.; Mollenhauer, B.; Müller, U.; Nilsson, C.; Whitwell, J.L.; Arzberger, T.; Englund, E.; Gelpi, E.; Giese, A.; Irwin, D.J.; Meissner, W.G.; Pantelyat, A.; Rajput, A.; van Swieten, J.C.; Troakes, C.; Antonini, A.; Bhatia, K.P.; Bordelon, Y.; Compta, Y.; Corvol, J.C.; Colosimo, C.; Dickson, D.W.; Dodel, R.; Ferguson, L.; Grossman, M.; Kassubek, J.; Krismer, F.; Levin, J.; Lorenzl, S.; Morris, H.R.; Nestor, P.; Oertel, W.H.; Poewe, W.; Rabinovici, G.; Rowe, J.B.; Schellenberg, G.D.; Seppi, K.; van Eimeren, T.; Wenning, G.K.; Boxer, A.L.; Golbe, L.I.; Litvan, I. Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord., 2017, 32(6), 853-864. doi: 10.1002/mds.26987 PMID: 28467028
  38. Postuma, R.B.; Berg, D.; Stern, M.; Poewe, W.; Olanow, C.W.; Oertel, W.; Obeso, J.; Marek, K.; Litvan, I.; Lang, A.E.; Halliday, G.; Goetz, C.G.; Gasser, T.; Dubois, B.; Chan, P.; Bloem, B.R.; Adler, C.H.; Deuschl, G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord., 2015, 30(12), 1591-1601. doi: 10.1002/mds.26424 PMID: 26474316
  39. Armstrong, M.J.; Litvan, I.; Lang, A.E.; Bak, T.H.; Bhatia, K.P.; Borroni, B.; Boxer, A.L.; Dickson, D.W.; Grossman, M.; Hallett, M.; Josephs, K.A.; Kertesz, A.; Lee, S.E.; Miller, B.L.; Reich, S.G.; Riley, D.E.; Tolosa, E.; Tröster, A.I.; Vidailhet, M.; Weiner, W.J. Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80(5), 496-503. doi: 10.1212/WNL.0b013e31827f0fd1 PMID: 23359374
  40. Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry, 1992, 55(3), 181-184. doi: 10.1136/jnnp.55.3.181 PMID: 1564476
  41. Joutsa, J.; Gardberg, M.; Röyttä, M.; Kaasinen, V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat. Disord., 2014, 20(8), 840-844. doi: 10.1016/j.parkreldis.2014.04.019 PMID: 24816002
  42. Koga, S.; Aoki, N.; Uitti, R.J.; van Gerpen, J.A.; Cheshire, W.P.; Josephs, K.A.; Wszolek, Z.K.; Langston, J.W.; Dickson, D.W. When DLB, PD, and PSP masquerade as MSA. Neurology, 2015, 85(5), 404-412. doi: 10.1212/WNL.0000000000001807 PMID: 26138942
  43. Rizzo, G.; Copetti, M.; Arcuti, S.; Martino, D.; Fontana, A.; Logroscino, G. Accuracy of clinical diagnosis of Parkinson disease. Neurology, 2016, 86(6), 566-576. doi: 10.1212/WNL.0000000000002350 PMID: 26764028
  44. Adler, C.H.; Beach, T.G.; Hentz, J.G.; Shill, H.A.; Caviness, J.N.; Driver-Dunckley, E.; Sabbagh, M.N.; Sue, L.I.; Jacobson, S.A.; Belden, C.M.; Dugger, B.N. Low clinical diagnostic accuracy of early vs. advanced Parkinson disease: Clinicopathologic study. Neurology, 2014, 83(5), 406-412. doi: 10.1212/WNL.0000000000000641 PMID: 24975862
  45. Eckert, T.; Barnes, A.; Dhawan, V.; Frucht, S.; Gordon, M.F.; Feigin, A.S.; Eidelberg, D. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage, 2005, 26(3), 912-921. doi: 10.1016/j.neuroimage.2005.03.012 PMID: 15955501
  46. Meyer, P.T.; Frings, L.; Rücker, G.; Hellwig, S. 18 F-FDG PET in Parkinsonism: Differential diagnosis and evaluation of cognitive impairment. J. Nucl. Med., 2017, 58(12), 1888-1898. doi: 10.2967/jnumed.116.186403 PMID: 28912150
  47. Brajkovic, L.; Kostic, V.; Sobic-Saranovic, D.; Stefanova, E.; Jecmenica-Lukic, M.; Jesic, A.; Stojiljkovic, M.; Odalovic, S.; Gallivanone, F.; Castiglioni, I.; Radovic, B.; Trajkovic, G.; Artiko, V. The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurol. Res., 2017, 39(8), 675-684. doi: 10.1080/01616412.2017.1312211 PMID: 28378615
  48. Hellwig, S.; Amtage, F.; Kreft, A.; Buchert, R.; Winz, O.H.; Vach, W.; Spehl, T.S.; Rijntjes, M.; Hellwig, B.; Weiller, C.; Winkler, C.; Weber, W.A.; Tuscher, O.; Meyer, P.T. (1)(8)FFDG-PET is superior to (1)(2)(3)IIBZM-SPECT for the differential diagnosis of parkinsonism. Neurology, 2012, 79(13), 1314-1322. doi: 10.1212/WNL.0b013e31826c1b0a PMID: 22914831
  49. Tripathi, M.; Dhawan, V.; Peng, S.; Kushwaha, S.; Batla, A.; Jaimini, A.; D’Souza, M.M.; Sharma, R.; Saw, S.; Mondal, A. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology, 2013, 55(4), 483-492. doi: 10.1007/s00234-012-1132-7 PMID: 23314836
  50. Caminiti, S.P.; Alongi, P.; Majno, L.; Volontè, M.A.; Cerami, C.; Gianolli, L.; Comi, G.; Perani, D. Evaluation of an optimized 18Ffluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. Eur. J. Neurol., 2017, 24(5), 687-e26. doi: 10.1111/ene.13269 PMID: 28244178
  51. Tang, C.C.; Poston, K.L.; Eckert, T.; Feigin, A.; Frucht, S.; Gudesblatt, M.; Dhawan, V.; Lesser, M.; Vonsattel, J.P.; Fahn, S.; Eidelberg, D. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol., 2010, 9(2), 149-158. doi: 10.1016/S1474-4422(10)70002-8 PMID: 20061183
  52. Tripathi, M.; Tang, C.C.; Feigin, A.; De Lucia, I.; Nazem, A.; Dhawan, V.; Eidelberg, D. Automated differential diagnosis of early parkinsonism using metabolic brain networks: A validation study. J. Nucl. Med., 2016, 57(1), 60-66. doi: 10.2967/jnumed.115.161992 PMID: 26449840
  53. Brumberg, J.; Isaias, I.U. SPECT molecular imaging in atypical parkinsonism. Int. Rev. Neurobiol., 2018, 142, 37-65. doi: 10.1016/bs.irn.2018.08.006 PMID: 30409259
  54. Borghammer, P.; Chakravarty, M.; Jonsdottir, K.Y.; Sato, N.; Matsuda, H.; Ito, K.; Arahata, Y.; Kato, T.; Gjedde, A. Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: Probably even at early disease stages. Brain Struct. Funct., 2010, 214(4), 303-317. doi: 10.1007/s00429-010-0246-0 PMID: 20361208
  55. Alster, P.; Nieciecki, M.; Koziorowski, D.; Cacko, A.; Charzyńska, I.; Królicki, L.; Friedman, A. Is brain perfusion a differentiating feature in the comparison of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)? J. Clin. Neurosci., 2020, 77, 123-127. doi: 10.1016/j.jocn.2020.05.005 PMID: 32389545
  56. Kobayashi, Z.; Akaza, M.; Ishihara, S.; Tomimitsu, H.; Inadome, Y.; Arai, T.; Akiyama, H.; Shintani, S. Thalamic hypoperfusion in early stage of progressive supranuclear palsy(Richardson’s syndrome): Report of an autopsy-confirmed case. J. Neurol. Sci., 2013, 335(1-2), 224-227. doi: 10.1016/j.jns.2013.09.005 PMID: 24075472
  57. Varrone, A.; Pagani, M.; Salvatore, E.; Salmaso, D.; Sansone, V.; Amboni, M.; Nobili, F.; De Michele, G.; Filla, A.; Barone, P.; Pappatà, S.; Salvatore, M. Identification by 99mTcECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson’s disease. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(7), 1071-1081. doi: 10.1007/s00259-006-0344-7 PMID: 17245531
  58. Kimura, N.; Hanaki, S.; Masuda, T.; Hanaoka, T.; Hazama, Y.; Okazaki, T.; Arakawa, R.; Kumamoto, T. Brain perfusion differences in Parkinsonian disorders. Mov. Disord., 2011, 26(14), 2530-2537. doi: 10.1002/mds.23915 PMID: 21830234
  59. Murakami, N.; Sako, W.; Haji, S.; Furukawa, T.; Otomi, Y.; Otsuka, H.; Izumi, Y.; Harada, M.; Kaji, R. Differences in cerebellar perfusion between Parkinson’s disease and multiple system atrophy. J. Neurol. Sci., 2020, 409, 116627. doi: 10.1016/j.jns.2019.116627 PMID: 31865188
  60. Alster, P.; Nieciecki, M.; Koziorowski, D.M.; Cacko, A.; Charzyńska, I.; Królicki, L.; Friedman, A. Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy. Medicine (Baltimore), 2019, 98(30), e16603. doi: 10.1097/MD.0000000000016603 PMID: 31348305
  61. Quattrone, A.; Nicoletti, G.; Messina, D.; Fera, F.; Condino, F.; Pugliese, P.; Lanza, P.; Barone, P.; Morgante, L.; Zappia, M.; Aguglia, U.; Gallo, O. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology, 2008, 246(1), 214-221. doi: 10.1148/radiol.2453061703 PMID: 17991785
  62. Matsuura, K.; Ii, Y.; Maeda, M.; Tabei, K.; Satoh, M.; Umino, M.; Miyashita, K.; Ishikawa, H.; Shindo, A.; Tomimoto, H. Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia. Parkinsonism Relat. Disord., 2021, 87, 75-81. doi: 10.1016/j.parkreldis.2021.05.002 PMID: 34000497
  63. Nigro, S.; Antonini, A.; Vaillancourt, D.E.; Seppi, K.; Ceravolo, R.; Strafella, A.P.; Augimeri, A.; Quattrone, A.; Morelli, M.; Weis, L.; Fiorenzato, E.; Biundo, R.; Burciu, R.G.; Krismer, F.; McFarland, N.R.; Mueller, C.; Gizewski, E.R.; Cosottini, M.; Del Prete, E.; Mazzucchi, S.; Quattrone, A. Automated MRI classification in progressive supranuclear palsy: A large international cohort study. Mov. Disord., 2020, 35(6), 976-983. doi: 10.1002/mds.28007 PMID: 32092195
  64. Mangesius, S.; Hussl, A.; Krismer, F.; Mahlknecht, P.; Reiter, E.; Tagwercher, S.; Djamshidian, A.; Schocke, M.; Esterhammer, R.; Wenning, G.; Müller, C.; Scherfler, C.; Gizewski, E.R.; Poewe, W.; Seppi, K. MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism Relat. Disord., 2018, 46, 47-55. doi: 10.1016/j.parkreldis.2017.10.020 PMID: 29126761
  65. Morelli, M.; Arabia, G.; Salsone, M.; Novellino, F.; Giofrè, L.; Paletta, R.; Messina, D.; Nicoletti, G.; Condino, F.; Gallo, O.; Lanza, P.; Quattrone, A. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov. Disord., 2011, 26(3), 527-533. doi: 10.1002/mds.23529 PMID: 21287599
  66. Constantinides, V.C.; Paraskevas, G.P.; Velonakis, G.; Toulas, P.; Stamboulis, E.; Kapaki, E. MRI planimetry and magnetic resonance parkinsonism index in the differential diagnosis of patients with parkinsonism. AJNR Am. J. Neuroradiol., 2018, 39(6), 1047-1051. doi: 10.3174/ajnr.A5618 PMID: 29622555
  67. Archer, D.B.; Mitchell, T.; Burciu, R.G.; Yang, J.; Nigro, S.; Quattrone, A.; Quattrone, A.; Jeromin, A.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Magnetic resonance imaging and neurofilament light in the differentiation of parkinsonism. Mov. Disord., 2020, 35(8), 1388-1395. doi: 10.1002/mds.28060 PMID: 32357259
  68. Quattrone, A.; Antonini, A.; Vaillancourt, D.E.; Seppi, K.; Ceravolo, R.; Strafella, A.P.; Morelli, M.; Nigro, S.; Vescio, B.; Bianco, M.G.; Vasta, R.; Arcuri, P.P.; Weis, L.; Fiorenzato, E.; Biundo, R.; Burciu, R.G.; Krismer, F.; McFarland, N.R.; Mueller, C.; Gizewski, E.R.; Cosottini, M.; Del Prete, E.; Mazzucchi, S.; Quattrone, A. A New MRI measure to early differentiate progressive supranuclear palsy from de novo Parkinson’s Disease in clinical practice: An international study. Mov. Disord., 2021, 36(3), 681-689. doi: 10.1002/mds.28364 PMID: 33151015
  69. Quattrone, A.; Morelli, M.; Nigro, S.; Quattrone, A.; Vescio, B.; Arabia, G.; Nicoletti, G.; Nisticò, R.; Salsone, M.; Novellino, F.; Barbagallo, G.; Le Piane, E.; Pugliese, P.; Bosco, D.; Vaccaro, M.G.; Chiriaco, C.; Sabatini, U.; Vescio, V.; Stanà, C.; Rocca, F.; Gullà, D.; Caracciolo, M. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson’s disease. Parkinsonism Relat. Disord., 2018, 54, 3-8. doi: 10.1016/j.parkreldis.2018.07.016 PMID: 30068492
  70. Quattrone, A.; Morelli, M.; Vescio, B.; Nigro, S.; Le Piane, E.; Sabatini, U.; Caracciolo, M.; Vescio, V.; Quattrone, A.; Barbagallo, G.; Stanà, C.; Nicoletti, G.; Arabia, G.; Nisticò, R.; Novellino, F.; Salsone, M. Refining initial diagnosis of Parkinson’s disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study. Mov. Disord., 2019, 34(4), 487-495. doi: 10.1002/mds.27621 PMID: 30759325
  71. Chougar, L.; Faouzi, J.; Pyatigorskaya, N.; Yahia-Cherif, L.; Gaurav, R.; Biondetti, E.; Villotte, M.; Valabrègue, R.; Corvol, J.C.; Brice, A.; Mariani, L.L.; Cormier, F.; Vidailhet, M.; Dupont, G.; Piot, I.; Grabli, D.; Payan, C.; Colliot, O.; Degos, B.; Lehéricy, S. Automated categorization of parkinsonian syndromes using magnetic resonance imaging in a clinical setting. Mov. Disord., 2021, 36(2), 460-470. doi: 10.1002/mds.28348 PMID: 33137232
  72. Hofer, S.; Frahm, J. Topography of the human corpus callosum revisited—Comprehensive fiber tractography using diffusion tensor magnetic resonance imaging. Neuroimage, 2006, 32(3), 989-994. doi: 10.1016/j.neuroimage.2006.05.044 PMID: 16854598
  73. Pasternak, O.; Sochen, N.; Gur, Y.; Intrator, N.; Assaf, Y. Free water elimination and mapping from diffusion MRI. Magn. Reson. Med., 2009, 62(3), 717-730. doi: 10.1002/mrm.22055 PMID: 19623619
  74. Mitchell, T.; Archer, D.B.; Chu, W.T.; Coombes, S.A.; Lai, S.; Wilkes, B.J.; McFarland, N.R.; Okun, M.S.; Black, M.L.; Herschel, E.; Simuni, T.; Comella, C.; Xie, T.; Li, H.; Parrish, T.B.; Kurani, A.S.; Corcos, D.M.; Vaillancourt, D.E. Neurite orientation dispersion and density imaging (NODDI) and free‐water imaging in Parkinsonism. Hum. Brain Mapp., 2019, 40(17), 5094-5107. doi: 10.1002/hbm.24760 PMID: 31403737
  75. Wang, Y.; Wang, Q.; Haldar, J.P.; Yeh, F.C.; Xie, M.; Sun, P.; Tu, T.W.; Trinkaus, K.; Klein, R.S.; Cross, A.H.; Song, S.K. Quantification of increased cellularity during inflammatory demyelination. Brain, 2011, 134(12), 3590-3601. doi: 10.1093/brain/awr307 PMID: 22171354
  76. Febo, M.; Perez, P.D.; Ceballos-Diaz, C.; Colon-Perez, L.M.; Zeng, H.; Ofori, E.; Golde, T.E.; Vaillancourt, D.E.; Chakrabarty, P. Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-γ. Brain Struct. Funct., 2020, 225(1), 427-439. doi: 10.1007/s00429-019-02017-1 PMID: 31894407
  77. Planetta, P.J.; Ofori, E.; Pasternak, O.; Burciu, R.G.; Shukla, P.; DeSimone, J.C.; Okun, M.S.; McFarland, N.R.; Vaillancourt, D.E. Free-water imaging in Parkinson’s disease and atypical parkinsonism. Brain, 2016, 139(2), 495-508. doi: 10.1093/brain/awv361 PMID: 26705348
  78. Archer, D.B.; Bricker, J.T.; Chu, W.T.; Burciu, R.G.; McCracken, J.L.; Lai, S.; Coombes, S.A.; Fang, R.; Barmpoutis, A.; Corcos, D.M.; Kurani, A.S.; Mitchell, T.; Black, M.L.; Herschel, E.; Simuni, T.; Parrish, T.B.; Comella, C.; Xie, T.; Seppi, K.; Bohnen, N.I.; Müller, M.L.T.M.; Albin, R.L.; Krismer, F.; Du, G.; Lewis, M.M.; Huang, X.; Li, H.; Pasternak, O.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): A multicentre machine learning study. Lancet Digit. Health, 2019, 1(5), e222-e231. doi: 10.1016/S2589-7500(19)30105-0 PMID: 32259098
  79. Burciu, R.G.; Ofori, E.; Archer, D.B.; Wu, S.S.; Pasternak, O.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Progression marker of Parkinson’s disease: A 4-year multi-site imaging study. Brain, 2017, 140(8), 2183-2192. doi: 10.1093/brain/awx146 PMID: 28899020
  80. Guttuso, T., Jr; Bergsland, N.; Hagemeier, J.; Lichter, D.G.; Pasternak, O.; Zivadinov, R. Substantia nigra free water increases longitudinally in Parkinson Disease. AJNR Am. J. Neuroradiol., 2018, 39(3), 479-484. doi: 10.3174/ajnr.A5545 PMID: 29419398
  81. Ofori, E.; Krismer, F.; Burciu, R.G.; Pasternak, O.; McCracken, J.L.; Lewis, M.M.; Du, G.; McFarland, N.R.; Okun, M.S.; Poewe, W.; Mueller, C.; Gizewski, E.R.; Schocke, M.; Kremser, C.; Li, H.; Huang, X.; Seppi, K.; Vaillancourt, D.E. Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. Mov. Disord., 2017, 32(10), 1457-1464. doi: 10.1002/mds.27100 PMID: 28714593
  82. Ofori, E.; Pasternak, O.; Planetta, P.J.; Burciu, R.; Snyder, A.; Febo, M.; Golde, T.E.; Okun, M.S.; Vaillancourt, D.E. Increased free water in the substantia nigra of Parkinson’s disease: A single-site and multi-site study. Neurobiol. Aging, 2015, 36(2), 1097-1104. doi: 10.1016/j.neurobiolaging.2014.10.029 PMID: 25467638
  83. Ofori, E.; Pasternak, O.; Planetta, P.J.; Li, H.; Burciu, R.G.; Snyder, A.F.; Lai, S.; Okun, M.S.; Vaillancourt, D.E. Longitudinal changes in free-water within the substantia nigra of Parkinson’s disease. Brain, 2015, 138(8), 2322-2331. doi: 10.1093/brain/awv136 PMID: 25981960
  84. Yang, J.; Archer, D.B.; Burciu, R.G.; Müller, M.L.T.M.; Roy, A.; Ofori, E.; Bohnen, N.I.; Albin, R.L.; Vaillancourt, D.E. Multimodal dopaminergic and free-water imaging in Parkinson’s disease. Parkinsonism Relat. Disord., 2019, 62, 10-15. doi: 10.1016/j.parkreldis.2019.01.007 PMID: 30639168
  85. Zhou, L.; Li, G.; Zhang, Y.; Zhang, M.; Chen, Z.; Zhang, L.; Wang, X.; Zhang, M.; Ye, G.; Li, Y.; Chen, S.; Li, B.; Wei, H.; Liu, J. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. Brain, 2021, 144(5), 1488-1497. doi: 10.1093/brain/awab039 PMID: 33880500
  86. Mitchell, T.; Wilkes, B.J.; Archer, D.B.; Chu, W.T.; Coombes, S.A.; Lai, S.; McFarland, N.R.; Okun, M.S.; Black, M.L.; Herschel, E.; Simuni, T.; Comella, C.; Afshari, M.; Xie, T.; Li, H.; Parrish, T.B.; Kurani, A.S.; Corcos, D.M.; Vaillancourt, D.E. Advanced diffusion imaging to track progression in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neuroimage Clin., 2022, 34, 103022. doi: 10.1016/j.nicl.2022.103022 PMID: 35489192
  87. Guttuso, T., Jr; Sirica, D.; Tosun, D.; Zivadinov, R.; Pasternak, O.; Weintraub, D.; Baglio, F.; Bergsland, N. Thalamic dorsomedial nucleus free water correlates with cognitive decline in Parkinson’s Disease. Mov. Disord., 2022, 37(3), 490-501. doi: 10.1002/mds.28886 PMID: 34936139
  88. Boelmans, K.; Bodammer, N.C.; Suchorska, B.; Kaufmann, J.; Ebersbach, G.; Heinze, H.J.; Niehaus, L. Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson’s disease. Parkinsonism Relat. Disord., 2010, 16(8), 498-502. doi: 10.1016/j.parkreldis.2010.05.006 PMID: 20573537
  89. Erbetta, A.; Mandelli, M.L.; Savoiardo, M.; Grisoli, M.; Bizzi, A.; Soliveri, P.; Chiapparini, L.; Prioni, S.; Bruzzone, M.G.; Girotti, F. Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Am. J. Neuroradiol., 2009, 30(8), 1482-1487. doi: 10.3174/ajnr.A1615 PMID: 19589886
  90. Rizzo, G.; Martinelli, P.; Manners, D.; Scaglione, C.; Tonon, C.; Cortelli, P.; Malucelli, E.; Capellari, S.; Testa, C.; Parchi, P.; Montagna, P.; Barbiroli, B.; Lodi, R. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson’s disease. Brain, 2008, 131(10), 2690-2700. doi: 10.1093/brain/awn195 PMID: 18819991
  91. Whitwell, J.L.; Schwarz, C.G.; Reid, R.I.; Kantarci, K.; Jack, C.R., Jr; Josephs, K.A. Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat. Disord., 2014, 20(5), 493-498. doi: 10.1016/j.parkreldis.2014.01.023 PMID: 24656943
  92. Boelmans, K.; Kaufmann, J.; Bodammer, N.; Ebersbach, G.; Behlau, G.; Heinze, H.J.; Niehaus, L. Involvement of motor pathways in corticobasal syndrome detected by diffusion tensor tractography. Mov. Disord., 2009, 24(2), 168-175. doi: 10.1002/mds.22193 PMID: 18973249
  93. Gore, J.C. Principles and practice of functional MRI of the human brain. J. Clin. Invest., 2003, 112(1), 4-9. doi: 10.1172/JCI200319010 PMID: 12840051
  94. Baggio, H.C.; Abos, A.; Segura, B.; Campabadal, A.; Uribe, C.; Giraldo, D.M.; Perez-Soriano, A.; Muñoz, E.; Compta, Y.; Junque, C.; Marti, M.J. Cerebellar resting-state functional connectivity in Parkinson’s disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level. Neuroimage Clin., 2019, 22, 101720. doi: 10.1016/j.nicl.2019.101720 PMID: 30785051
  95. Ballarini, T.; Albrecht, F.; Mueller, K.; Jech, R.; Diehl-Schmid, J.; Fliessbach, K.; Kassubek, J.; Lauer, M.; Fassbender, K.; Schneider, A.; Synofzik, M.; Wiltfang, J.; Otto, M.; Schroeter, M.L. Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. Neuroimage Clin., 2020, 25, 102112. doi: 10.1016/j.nicl.2019.102112 PMID: 31821953
  96. Brown, J.A.; Hua, A.Y.; Trujillo, A.; Attygalle, S.; Binney, R.J.; Spina, S.; Lee, S.E.; Kramer, J.H.; Miller, B.L.; Rosen, H.J.; Boxer, A.L.; Seeley, W.W. Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. Neuroimage Clin., 2017, 16, 564-574. doi: 10.1016/j.nicl.2017.09.008 PMID: 28951832
  97. Bharti, K.; Bologna, M.; Upadhyay, N.; Piattella, M.C.; Suppa, A.; Petsas, N.; Giannì, C.; Tona, F.; Berardelli, A.; Pantano, P. Abnormal resting-state functional connectivity in progressive supranuclear palsy and corticobasal syndrome. Front. Neurol., 2017, 8, 248. doi: 10.3389/fneur.2017.00248 PMID: 28634465
  98. Upadhyay, N.; Suppa, A.; Piattella, M.C.; Giannì, C.; Bologna, M.; Di Stasio, F.; Petsas, N.; Tona, F.; Fabbrini, G.; Berardelli, A.; Pantano, P. Functional disconnection of thalamic and cerebellar dentate nucleus networks in progressive supranuclear palsy and corticobasal syndrome. Parkinsonism Relat. Disord., 2017, 39, 52-57. doi: 10.1016/j.parkreldis.2017.03.008 PMID: 28318985
  99. Prodoehl, J.; Burciu, R.G.; Vaillancourt, D.E. Resting state functional magnetic resonance imaging in Parkinson’s disease. Curr. Neurol. Neurosci. Rep., 2014, 14(6), 448. doi: 10.1007/s11910-014-0448-6 PMID: 24744021
  100. Rosskopf, J.; Gorges, M.; Müller, H.P.; Pinkhardt, E.H.; Ludolph, A.C.; Kassubek, J. Hyperconnective and hypoconnective cortical and subcortical functional networks in multiple system atrophy. Parkinsonism Relat. Disord., 2018, 49, 75-80. doi: 10.1016/j.parkreldis.2018.01.012 PMID: 29352721
  101. Yao, Q.; Zhu, D.; Li, F.; Xiao, C.; Lin, X.; Huang, Q.; Shi, J. Altered functional and causal connectivity of cerebello-cortical circuits between multiple system atrophy (Parkinsonian Type) and Parkinson’s Disease. Front. Aging Neurosci., 2017, 9, 266. doi: 10.3389/fnagi.2017.00266 PMID: 28848423
  102. Vo, A.; Sako, W.; Fujita, K.; Peng, S.; Mattis, P.J.; Skidmore, F.M.; Ma, Y.; Uluğ, A.M.; Eidelberg, D. Parkinson’s disease-related network topographies characterized with resting state functional MRI. Hum. Brain Mapp., 2017, 38(2), 617-630. doi: 10.1002/hbm.23260 PMID: 27207613
  103. Rommal, A.; Vo, A.; Schindlbeck, K.A.; Greuel, A.; Ruppert, M.C.; Eggers, C.; Eidelberg, D. Parkinson’s disease-related pattern (PDRP) identified using resting-state functional MRI: Validation study. Neuroimage. Reports, 2021, 1(3), 100026. doi: 10.1016/j.ynirp.2021.100026
  104. Ma, Y.; Tang, C.; Spetsieris, P.G.; Dhawan, V.; Eidelberg, D. Abnormal metabolic network activity in Parkinson’s disease: Test-retest reproducibility. J. Cereb. Blood Flow Metab., 2007, 27(3), 597-605. doi: 10.1038/sj.jcbfm.9600358 PMID: 16804550
  105. Burciu, R.G.; Chung, J.W.; Shukla, P.; Ofori, E.; Li, H.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. Neurology, 2016, 87(7), 709-717. doi: 10.1212/WNL.0000000000002985 PMID: 27421545
  106. Burciu, R.G.; Ofori, E.; Shukla, P.; Pasternak, O.; Chung, J.W.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Free-water and BOLD imaging changes in Parkinson’s disease patients chronically treated with a MAO-B inhibitor. Hum. Brain Mapp., 2016, 37(8), 2894-2903. doi: 10.1002/hbm.23213 PMID: 27089850
  107. Planetta, P.J.; Kurani, A.S.; Shukla, P.; Prodoehl, J.; Corcos, D.M.; Comella, C.L.; McFarland, N.R.; Okun, M.S.; Vaillancourt, D.E. Distinct functional and macrostructural brain changes in Parkinson’s disease and multiple system atrophy. Hum. Brain Mapp., 2015, 36(3), 1165-1179. doi: 10.1002/hbm.22694 PMID: 25413603
  108. Eckert, T.; Tang, C.; Ma, Y.; Brown, N.; Lin, T.; Frucht, S.; Feigin, A.; Eidelberg, D. Abnormal metabolic networks in atypical parkinsonism. Mov. Disord., 2008, 23(5), 727-733. doi: 10.1002/mds.21933 PMID: 18186116
  109. Borogovac, A.; Asllani, I. Arterial Spin Labeling (ASL) fMRI: Advantages, theoretical constrains, and experimental challenges in neurosciences. Int. J. Biomed. Imaging, 2012, 2012, 818456. PMID: 22966219
  110. Soldozy, S.; Galindo, J.; Snyder, H.; Ali, Y.; Norat, P.; Yağmurlu, K.; Sokolowski, J.D.; Sharifi, K.; Tvrdik, P.; Park, M.S.; Kalani, M.Y.S. Clinical utility of arterial spin labeling imaging in disorders of the nervous system. Neurosurg. Focus, 2019, 47(6), E5. doi: 10.3171/2019.9.FOCUS19567 PMID: 31786550
  111. Melzer, T.R.; Watts, R.; MacAskill, M.R.; Pearson, J.F.; Rüeger, S.; Pitcher, T.L.; Livingston, L.; Graham, C.; Keenan, R.; Shankaranarayanan, A.; Alsop, D.C.; Dalrymple-Alford, J.C.; Anderson, T.J. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease. Brain, 2011, 134(3), 845-855. doi: 10.1093/brain/awq377 PMID: 21310726
  112. Cheng, L.; Wu, X.; Guo, R.; Wang, Y.; Wang, W.; He, P.; Lin, H.; Shen, J. Discriminative pattern of reduced cerebral blood flow in Parkinson’s disease and Parkinsonism-Plus syndrome: an ASL-MRI study. BMC Med. Imaging, 2020, 20(1), 78. doi: 10.1186/s12880-020-00479-y PMID: 32660445
  113. Cui, B.; Zheng, W.; Ren, S.; Chen, Z.; Wang, Z. Differentiation of cerebellum-type and parkinson-type of multiple system atrophy by using multimodal MRI parameters. Front. Aging Neurosci., 2021, 13, 687649. doi: 10.3389/fnagi.2021.687649 PMID: 34413766
  114. Erro, R.; Ponticorvo, S.; Manara, R.; Barone, P.; Picillo, M.; Scannapieco, S.; Cicarelli, G.; Squillante, M.; Volpe, G.; Esposito, F.; Pellecchia, M.T. Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. Parkinsonism Relat. Disord., 2020, 72, 49-55. doi: 10.1016/j.parkreldis.2020.02.009 PMID: 32109737
  115. Zheng, W.; Ren, S.; Zhang, H.; Liu, M.; Zhang, Q.; Chen, Z.; Wang, Z. Spatial patterns of decreased cerebral blood flow and functional connectivity in multiple system atrophy (Cerebellar-Type): A combined arterial spin labeling perfusion and resting state functional magnetic resonance imaging study. Front. Neurosci., 2019, 13, 777. doi: 10.3389/fnins.2019.00777 PMID: 31417345
  116. Fernández-Seara, M.A.; Mengual, E.; Vidorreta, M.; Aznárez-Sanado, M.; Loayza, F.R.; Villagra, F.; Irigoyen, J.; Pastor, M.A. Cortical hypoperfusion in Parkinson’s disease assessed using arterial spin labeled perfusion MRI. Neuroimage, 2012, 59(3), 2743-2750. doi: 10.1016/j.neuroimage.2011.10.033 PMID: 22032942
  117. Pelizzari, L.; Di Tella, S.; Rossetto, F.; Laganà, M.M.; Bergsland, N.; Pirastru, A.; Meloni, M.; Nemni, R.; Baglio, F. Parietal perfusion alterations in Parkinson’s Disease patients without dementia. Front. Neurol., 2020, 11, 562. doi: 10.3389/fneur.2020.00562 PMID: 32655485
  118. Liu, Z.; Zhang, Y.; Wang, H.; Xu, D.; You, H.; Zuo, Z.; Feng, F. Altered cerebral perfusion and microstructure in advanced Parkinson’s disease and their associations with clinical features. Neurol. Res., 2022, 44(1), 47-56. doi: 10.1080/01616412.2021.1954842 PMID: 34313185
  119. Puig, O.; Henriksen, O.M.; Vestergaard, M.B.; Hansen, A.E.; Andersen, F.L.; Ladefoged, C.N.; Rostrup, E.; Larsson, H.B.W.; Lindberg, U.; Law, I. Comparison of simultaneous arterial spin labeling MRI and 15 O-H 2 O PET measurements of regional cerebral blood flow in rest and altered perfusion states. J. Cereb. Blood Flow Metab., 2020, 40(8), 1621-1633. doi: 10.1177/0271678X19874643 PMID: 31500521
  120. Helmich, R.C. The cerebral basis of Parkinsonian tremor: A network perspective. Mov. Disord., 2018, 33(2), 219-231. doi: 10.1002/mds.27224 PMID: 29119634
  121. Dirkx, M.F.; den Ouden, H.; Aarts, E.; Timmer, M.; Bloem, B.R.; Toni, I.; Helmich, R.C. The cerebral network of Parkinson’s Tremor: An effective connectivity fMRI study. J. Neurosci., 2016, 36(19), 5362-5372. doi: 10.1523/JNEUROSCI.3634-15.2016 PMID: 27170132
  122. Helmich, R.C.; Janssen, M.J.R.; Oyen, W.J.G.; Bloem, B.R.; Toni, I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann. Neurol., 2011, 69(2), 269-281. doi: 10.1002/ana.22361 PMID: 21387372
  123. Fujioka, S.; Algom, A.A.; Murray, M.E.; Sanchez-Contreras, M.Y.; Tacik, P.; Tsuboi, Y.; Van Gerpen, J.A.; Uitti, R.J.; Rademakers, R.; Ross, O.A.; Wszolek, Z.K.; Dickson, D.W. Tremor in progressive supranuclear palsy. Parkinsonism Relat. Disord., 2016, 27, 93-97. doi: 10.1016/j.parkreldis.2016.03.015 PMID: 27039056
  124. Kaindlstorfer, C.; Granata, R.; Wenning, G.K. Tremor in Multiple System Atrophy-a review. Tremor Other Hyperkinet. Mov. (N.Y.), 2013, 3, 03. doi: 10.5334/tohm.166 PMID: 24116345
  125. Pal, P.K.; Mailankody, P.; Netravathi, M. Review of tremor in Parkinson’s disease and atypical parkinsonian disorders. Neurol. India, 2017, 65(5), 1083-1090. doi: 10.4103/neuroindia.NI_880_16 PMID: 28879902
  126. Su, D.; Yang, S.; Hu, W.; Wang, D.; Kou, W.; Liu, Z.; Wang, X.; Wang, Y.; Ma, H.; Sui, Y.; Zhou, J.; Pan, H.; Feng, T. The characteristics of tremor motion help identify Parkinson’s Disease and multiple system atrophy. Front. Neurol., 2020, 11, 540. doi: 10.3389/fneur.2020.00540 PMID: 32754107
  127. Berg, D.; Postuma, R.B.; Bloem, B.; Chan, P.; Dubois, B.; Gasser, T.; Goetz, C.G.; Halliday, G.M.; Hardy, J.; Lang, A.E.; Litvan, I.; Marek, K.; Obeso, J.; Oertel, W.; Olanow, C.W.; Poewe, W.; Stern, M.; Deuschl, G. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov. Disord., 2014, 29(4), 454-462. doi: 10.1002/mds.25844 PMID: 24619848
  128. Mantri, S.; Morley, J.F.; Siderowf, A.D. The importance of preclinical diagnostics in Parkinson disease. Parkinsonism Relat. Disord., 2019, 64, 20-28. doi: 10.1016/j.parkreldis.2018.09.011 PMID: 30224266
  129. Noyce, A.J.; Lees, A.J.; Schrag, A.E. The prediagnostic phase of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 2016, 87(8), 871-878. doi: 10.1136/jnnp-2015-311890 PMID: 26848171
  130. Pellicano, C.; Benincasa, D.; Pisani, V.; Buttarelli, F.R.; Giovannelli, M.; Pontieri, F.E. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr. Dis. Treat., 2007, 3(1), 145-151. doi: 10.2147/nedt.2007.3.1.145 PMID: 19300544
  131. Postuma, R.B.; Aarsland, D.; Barone, P.; Burn, D.J.; Hawkes, C.H.; Oertel, W.; Ziemssen, T. Identifying prodromal Parkinson’s disease: Pre-Motor disorders in Parkinson’s disease. Mov. Disord., 2012, 27(5), 617-626. doi: 10.1002/mds.24996 PMID: 22508280
  132. Greffard, S.; Verny, M.; Bonnet, A.M.; Beinis, J.Y.; Gallinari, C.; Meaume, S.; Piette, F.; Hauw, J.J.; Duyckaerts, C. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol., 2006, 63(4), 584-588. doi: 10.1001/archneur.63.4.584 PMID: 16606773
  133. Barber, T.R.; Klein, J.C.; Mackay, C.E.; Hu, M.T.M. Neuroimaging in pre-motor Parkinson’s disease. Neuroimage Clin., 2017, 15, 215-227. doi: 10.1016/j.nicl.2017.04.011 PMID: 28529878
  134. Klein, C.; Westenberger, A. Genetics of Parkinson’s disease. Cold Spring Harb. Perspect. Med., 2012, 2(1), a008888. doi: 10.1101/cshperspect.a008888 PMID: 22315721
  135. Healy, D.G.; Falchi, M.; O’Sullivan, S.S.; Bonifati, V.; Durr, A.; Bressman, S.; Brice, A.; Aasly, J.; Zabetian, C.P.; Goldwurm, S.; Ferreira, J.J.; Tolosa, E.; Kay, D.M.; Klein, C.; Williams, D.R.; Marras, C.; Lang, A.E.; Wszolek, Z.K.; Berciano, J.; Schapira, A.H.V.; Lynch, T.; Bhatia, K.P.; Gasser, T.; Lees, A.J.; Wood, N.W.; International, L.C. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case-control study. Lancet Neurol., 2008, 7(7), 583-590. doi: 10.1016/S1474-4422(08)70117-0 PMID: 18539534
  136. Marder, K.; Wang, Y.; Alcalay, R.N.; Mejia-Santana, H.; Tang, M.X.; Lee, A.; Raymond, D.; Mirelman, A.; Saunders-Pullman, R.; Clark, L.; Ozelius, L.; Orr-Urtreger, A.; Giladi, N.; Bressman, S.; Consortium, L.A.J. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology, 2015, 85(1), 89-95. doi: 10.1212/WNL.0000000000001708 PMID: 26062626
  137. Sierra, M.; González-Aramburu, I.; Sánchez-Juan, P.; Sánchez-Quintana, C.; Polo, J.M.; Berciano, J.; Combarros, O.; Infante, J. High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson’s disease patients in Cantabria (Spain). Mov. Disord., 2011, 26(13), 2343-2346. doi: 10.1002/mds.23965 PMID: 21954089
  138. Heinzel, S.; Berg, D.; Gasser, T.; Chen, H.; Yao, C.; Postuma, R.B. MDS Task Force on the Definition of Parkinson’s Disease. Update of the MDS research criteria for prodromal Parkinson’s disease. Mov. Disord., 2019, 34(10), 1464-1470. doi: 10.1002/mds.27802 PMID: 31412427
  139. Hu, M.T. REM sleep behavior disorder (RBD). Neurobiol. Dis., 2020, 143, 104996. doi: 10.1016/j.nbd.2020.104996 PMID: 32599063
  140. Galbiati, A.; Verga, L.; Giora, E.; Zucconi, M.; Ferini-Strambi, L. The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. Sleep Med. Rev., 2019, 43, 37-46. doi: 10.1016/j.smrv.2018.09.008 PMID: 30503716
  141. Postuma, R.B.; Iranzo, A.; Hu, M.; Högl, B.; Boeve, B.F.; Manni, R.; Oertel, W.H.; Arnulf, I.; Ferini-Strambi, L.; Puligheddu, M.; Antelmi, E.; Cochen De Cock, V.; Arnaldi, D.; Mollenhauer, B.; Videnovic, A.; Sonka, K.; Jung, K.Y.; Kunz, D.; Dauvilliers, Y.; Provini, F.; Lewis, S.J.; Buskova, J.; Pavlova, M.; Heidbreder, A.; Montplaisir, J.Y.; Santamaria, J.; Barber, T.R.; Stefani, A.; St Louis, E.K.; Terzaghi, M.; Janzen, A.; Leu-Semenescu, S.; Plazzi, G.; Nobili, F.; Sixel-Doering, F.; Dusek, P.; Bes, F.; Cortelli, P.; Ehgoetz Martens, K.; Gagnon, J.F.; Gaig, C.; Zucconi, M.; Trenkwalder, C.; Gan-Or, Z.; Lo, C.; Rolinski, M.; Mahlknecht, P.; Holzknecht, E.; Boeve, A.R.; Teigen, L.N.; Toscano, G.; Mayer, G.; Morbelli, S.; Dawson, B.; Pelletier, A. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study. Brain, 2019, 142(3), 744-759. doi: 10.1093/brain/awz030 PMID: 30789229
  142. Boeve, B.F.; Silber, M.H.; Ferman, T.J.; Lin, S.C.; Benarroch, E.E.; Schmeichel, A.M.; Ahlskog, J.E.; Caselli, R.J.; Jacobson, S.; Sabbagh, M.; Adler, C.; Woodruff, B.; Beach, T.G.; Iranzo, A.; Gelpi, E.; Santamaria, J.; Tolosa, E.; Singer, C.; Mash, D.C.; Luca, C.; Arnulf, I.; Duyckaerts, C.; Schenck, C.H.; Mahowald, M.W.; Dauvilliers, Y.; Graff-Radford, N.R.; Wszolek, Z.K.; Parisi, J.E.; Dugger, B.; Murray, M.E.; Dickson, D.W. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med., 2013, 14(8), 754-762. doi: 10.1016/j.sleep.2012.10.015 PMID: 23474058
  143. Arnaldi, D.; Chincarini, A.; Hu, M.T.; Sonka, K.; Boeve, B.; Miyamoto, T.; Puligheddu, M.; De Cock, V.C.; Terzaghi, M.; Plazzi, G.; Tachibana, N.; Morbelli, S.; Rolinski, M.; Dusek, P.; Lowe, V.; Miyamoto, M.; Figorilli, M.; Verbizier, D.; Bossert, I.; Antelmi, E.; Meli, R.; Barber, T.R.; Trnka, J.; Miyagawa, T.; Serra, A.; Pizza, F.; Bauckneht, M.; Bradley, K.M.; Zogala, D.; McGowan, D.R.; Jordan, L.; Manni, R.; Nobili, F. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain, 2021, 144(1), 278-287. doi: 10.1093/brain/awaa365 PMID: 33348363
  144. Iranzo, A.; Santamaría, J.; Valldeoriola, F.; Serradell, M.; Salamero, M.; Gaig, C.; Niñerola-Baizán, A.; Sánchez-Valle, R.; Lladó, A.; De Marzi, R.; Stefani, A.; Seppi, K.; Pavia, J.; Högl, B.; Poewe, W.; Tolosa, E.; Lomeña, F. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol., 2017, 82(3), 419-428. doi: 10.1002/ana.25026 PMID: 28833467
  145. Iranzo, A.; Stefani, A.; Niñerola-Baizan, A.; Stokner, H.; Serradell, M.; Vilas, D.; Holzknecht, E.; Gaig, C.; Pavia, J.; Lomeña, F.; Reyes, D.; Seppi, K.; Santamaria, J.; Högl, B.; Tolosa, E.; Poewe, W. Sleep Innsbruck Barcelona (SINBAR) Group. Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder. Neurology, 2020, 94(15), e1605-e1613. doi: 10.1212/WNL.0000000000009246 PMID: 32161031
  146. Iranzo, A.; Valldeoriola, F.; Lomeña, F.; Molinuevo, J.L.; Serradell, M.; Salamero, M.; Cot, A.; Ros, D.; Pavía, J.; Santamaria, J.; Tolosa, E. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study. Lancet Neurol., 2011, 10(9), 797-805. doi: 10.1016/S1474-4422(11)70152-1 PMID: 21802993
  147. Iranzo, A.; Lomeña, F.; Stockner, H.; Valldeoriola, F.; Vilaseca, I.; Salamero, M.; Molinuevo, J.L.; Serradell, M.; Duch, J.; Pavía, J.; Gallego, J.; Seppi, K.; Högl, B.; Tolosa, E.; Poewe, W.; Santamaria, J. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study. Lancet Neurol., 2010, 9(11), 1070-1077. doi: 10.1016/S1474-4422(10)70216-7 PMID: 20846908
  148. Arnaldi, D.; De Carli, F.; Picco, A.; Ferrara, M.; Accardo, J.; Bossert, I.; Famà, F.; Girtler, N.; Morbelli, S.; Sambuceti, G.; Nobili, F. Nigro-caudate dopaminergic deafferentation: A marker of REM sleep behavior disorder? Neurobiol. Aging, 2015, 36(12), 3300-3305. doi: 10.1016/j.neurobiolaging.2015.08.025 PMID: 26410306
  149. Eisensehr, I.; Linke, R.; Noachtar, S.; Schwarz, J.; Gildehaus, F.J.; Tatsch, K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Brain, 2000, 123(6), 1155-1160. doi: 10.1093/brain/123.6.1155 PMID: 10825354
  150. Li, Y.; Kang, W.; Yang, Q.; Zhang, L.; Zhang, L.; Dong, F.; Chen, S.; Liu, J. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology, 2017, 88(16), 1493-1500. doi: 10.1212/WNL.0000000000003838 PMID: 28330956
  151. Meles, S.K.; Vadasz, D.; Renken, R.J.; Sittig-Wiegand, E.; Mayer, G.; Depboylu, C.; Reetz, K.; Overeem, S.; Pijpers, A.; Reesink, F.E.; van Laar, T.; Heinen, L.; Teune, L.K.; Höffken, H.; Luster, M.; Kesper, K.; Adriaanse, S.M.; Booij, J.; Leenders, K.L.; Oertel, W.H. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Mov. Disord., 2017, 32(10), 1482-1486. doi: 10.1002/mds.27094 PMID: 28734065
  152. Bae, Y.J.; Kim, J.M.; Kim, K.J.; Kim, E.; Park, H.S.; Kang, S.Y.; Yoon, I.Y.; Lee, J.Y.; Jeon, B.; Kim, S.E. Loss of substantia nigra hyperintensity at 3.0-T MR imaging in idiopathic REM sleep behavior disorder: Comparison with 123 I-FP-CIT SPECT. Radiology, 2018, 287(1), 285-293. doi: 10.1148/radiol.2017162486 PMID: 29232183
  153. Yamada, G.; Ueki, Y.; Oishi, N.; Oguri, T.; Fukui, A.; Nakayama, M.; Sano, Y.; Kandori, A.; Kan, H.; Arai, N.; Sakurai, K.; Wada, I.; Matsukawa, N. Nigrostriatal dopaminergic dysfunction and altered functional connectivity in REM Sleep Behavior disorder with mild motor impairment. Front. Neurol., 2019, 10, 802. doi: 10.3389/fneur.2019.00802 PMID: 31404164
  154. Shin, J.H.; Lee, J.Y.; Kim, Y.K.; Shin, S.A.; Kim, H.; Nam, H.; Jeon, B. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology, 2020, 95(23), e3081-e3092. doi: 10.1212/WNL.0000000000010942 PMID: 32989104
  155. Stokholm, M.G.; Iranzo, A.; Østergaard, K.; Serradell, M.; Otto, M.; Svendsen, K.B.; Garrido, A.; Vilas, D.; Borghammer, P.; Santamaria, J.; Møller, A.; Gaig, C.; Brooks, D.J.; Tolosa, E.; Pavese, N. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol., 2017, 16(10), 789-796. doi: 10.1016/S1474-4422(17)30173-4 PMID: 28684245
  156. Albin, R.L.; Koeppe, R.A.; Chervin, R.D.; Consens, F.B.; Wernette, K.; Frey, K.A.; Aldrich, M.S. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology, 2000, 55(9), 1410-1412. doi: 10.1212/WNL.55.9.1410 PMID: 11087796
  157. Knudsen, K.; Fedorova, T.D.; Hansen, A.K.; Sommerauer, M.; Otto, M.; Svendsen, K.B.; Nahimi, A.; Stokholm, M.G.; Pavese, N.; Beier, C.P.; Brooks, D.J.; Borghammer, P. In-vivo staging of pathology in REM sleep behaviour disorder: A multimodality imaging case-control study. Lancet Neurol., 2018, 17(7), 618-628. doi: 10.1016/S1474-4422(18)30162-5 PMID: 29866443
  158. Biondetti, E.; Santin, M.D.; Valabrègue, R.; Mangone, G.; Gaurav, R.; Pyatigorskaya, N.; Hutchison, M.; Yahia-Cherif, L.; Villain, N.; Habert, M.O.; Arnulf, I.; Leu-Semenescu, S.; Dodet, P.; Vila, M.; Corvol, J.C.; Vidailhet, M.; Lehéricy, S. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease. Brain, 2021, 144(10), 3114-3125. doi: 10.1093/brain/awab191 PMID: 33978742
  159. Holtbernd, F.; Gagnon, J.F.; Postuma, R.B.; Ma, Y.; Tang, C.C.; Feigin, A.; Dhawan, V.; Vendette, M.; Soucy, J.P.; Eidelberg, D.; Montplaisir, J. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology, 2014, 82(7), 620-627. doi: 10.1212/WNL.0000000000000130 PMID: 24453082
  160. Shin, J.H.; Lee, J.Y.; Kim, Y.K.; Yoon, E.J.; Kim, H.; Nam, H.; Jeon, B. Parkinson disease-related brain metabolic patterns and neurodegeneration in Isolated REM Sleep behavior disorder. Neurology, 2021, 97(4), e378-e388. doi: 10.1212/WNL.0000000000012228 PMID: 34011571
  161. Wu, P.; Yu, H.; Peng, S.; Dauvilliers, Y.; Wang, J.; Ge, J.; Zhang, H.; Eidelberg, D.; Ma, Y.; Zuo, C. Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain, 2014, 137(12), 3122-3128. doi: 10.1093/brain/awu290 PMID: 25338949
  162. Kogan, R.V.; Janzen, A.; Meles, S.K.; Sittig, E.; Renken, R.J.; Gurvits, V.; Mayer, G.; Leenders, K.L.; Oertel, W.H.; Booij, J.; Reetz, K.; Overeem, S.; Pijpers, A.; Bernhard, F.; García, D.V.; Peretti, D.E.; Teune, L.K.; Reesink, F.E.; Kok, J.G. Four‐year follow‐up of 18FFluorodeoxyglucose positron emission tomography–based Parkinson’s disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression. Mov. Disord., 2021, 36(1), 230-235. doi: 10.1002/mds.28260 PMID: 32909650
  163. Hanyu, H.; Inoue, Y.; Sakurai, H.; Kanetaka, H.; Nakamura, M.; Miyamoto, T.; Sasai, T.; Iwamoto, T. Regional cerebral blood flow changes in patients with idiopathic REM sleep behavior disorder. Eur. J. Neurol., 2011, 18(5), 784-788. doi: 10.1111/j.1468-1331.2010.03283.x PMID: 21143707
  164. Mazza, S.; Soucy, J.P.; Gravel, P.; Michaud, M.; Postuma, R.; Massicotte-Marquez, J.; Decary, A.; Montplaisir, J. Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology, 2006, 67(9), 1618-1622. doi: 10.1212/01.wnl.0000242879.39415.49 PMID: 17101893
  165. Sakurai, H.; Hanyu, H.; Inoue, Y.; Kanetaka, H.; Nakamura, M.; Miyamoto, T.; Sasai, T.; Iwamoto, T. Longitudinal study of regional cerebral blood flow in elderly patients with idiopathic rapid eye movement sleep behavior disorder. Geriatr. Gerontol. Int., 2014, 14(1), 115-120. doi: 10.1111/ggi.12068 PMID: 23586530
  166. Shirakawa, S.I.; Takeuchi, N.; Uchimura, N.; Ohyama, T.; Maeda, H.; Abe, T.; Ishibashi, M.; Ohshima, Y.; Ohshima, H. Study of image findings in rapid eye movement sleep behavioural disorder. Psychiatry Clin. Neurosci., 2002, 56(3), 291-292. doi: 10.1046/j.1440-1819.2002.00961.x PMID: 12047600
  167. Vendette, M.; Gagnon, J.F.; Soucy, J.P.; Gosselin, N.; Postuma, R.B.; Tuineag, M.; Godin, I.; Montplaisir, J. Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder. Mov. Disord., 2011, 26(9), 1717-1724. doi: 10.1002/mds.23721 PMID: 21542022
  168. Vendette, M.; Montplaisir, J.; Gosselin, N.; Soucy, J.P.; Postuma, R.B.; Dang-Vu, T.T.; Gagnon, J.F. Brain perfusion anomalies in rapid eye movement sleep behavior disorder with mild cognitive impairment. Mov. Disord., 2012, 27(10), 1255-1261. doi: 10.1002/mds.25034 PMID: 22791632
  169. Dang-Vu, T.T.; Gagnon, J.F.; Vendette, M.; Soucy, J.P.; Postuma, R.B.; Montplaisir, J. Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder. Neurology, 2012, 79(24), 2302-2306. doi: 10.1212/WNL.0b013e318278b658 PMID: 23115214
  170. Ward, R.J.; Zucca, F.A.; Duyn, J.H.; Crichton, R.R.; Zecca, L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol., 2014, 13(10), 1045-1060. doi: 10.1016/S1474-4422(14)70117-6 PMID: 25231526
  171. Friedman, A.; Galazka-Friedman, J. The history of the research of iron in parkinsonian substantia nigra. J. Neural Transm., 2012, 119(12), 1507-1510. doi: 10.1007/s00702-012-0894-8 PMID: 22941506
  172. Duyn, J.H.; Schenck, J. Contributions to magnetic susceptibility of brain tissue. NMR Biomed., 2017, 30(4), e3546. doi: 10.1002/nbm.3546 PMID: 27240118
  173. Ruetten, P.P.R.; Gillard, J.H.; Graves, M.J. Introduction to quantitative susceptibility mapping and susceptibility weighted imaging. Br. J. Radiol., 2019, 92(1101), 20181016. doi: 10.1259/bjr.20181016 PMID: 30933548
  174. Yan, F.; He, N.; Lin, H.; Li, R. Iron deposition quantification: Applications in the brain and liver. J. Magn. Reson. Imaging, 2018, 48(2), 301-317. doi: 10.1002/jmri.26161 PMID: 29897645
  175. Langkammer, C.; Krebs, N.; Goessler, W.; Scheurer, E.; Ebner, F.; Yen, K.; Fazekas, F.; Ropele, S. Quantitative MR imaging of brain iron: A postmortem validation study. Radiology, 2010, 257(2), 455-462. doi: 10.1148/radiol.10100495 PMID: 20843991
  176. Sun, H.; Walsh, A.J.; Lebel, R.M.; Blevins, G.; Catz, I.; Lu, J.Q.; Johnson, E.S.; Emery, D.J.; Warren, K.G.; Wilman, A.H. Validation of quantitative susceptibility mapping with Perls’ iron staining for subcortical gray matter. Neuroimage, 2015, 105, 486-492. doi: 10.1016/j.neuroimage.2014.11.010 PMID: 25462797
  177. Wang, C.; Foxley, S.; Ansorge, O.; Bangerter-Christensen, S.; Chiew, M.; Leonte, A.; Menke, R.A.L.; Mollink, J.; Pallebage-Gamarallage, M.; Turner, M.R.; Miller, K.L.; Tendler, B.C. Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. Neuroimage, 2020, 222, 117216. doi: 10.1016/j.neuroimage.2020.117216 PMID: 32745677
  178. Pyatigorskaya, N.; Sanz-Morère, C.B.; Gaurav, R.; Biondetti, E.; Valabregue, R.; Santin, M.; Yahia-Cherif, L.; Lehéricy, S. Iron imaging as a diagnostic tool for Parkinson’s disease: A systematic review and meta-analysis. Front. Neurol., 2020, 11, 366. doi: 10.3389/fneur.2020.00366 PMID: 32547468
  179. Lee, J.H.; Lee, M.S. Brain Iron Accumulation in Atypical Parkinsonian Syndromes: In vivo MRI Evidences for Distinctive Patterns. Front. Neurol., 2019, 10, 74. doi: 10.3389/fneur.2019.00074 PMID: 30809185
  180. De Marzi, R.; Seppi, K.; Högl, B.; Müller, C.; Scherfler, C.; Stefani, A.; Iranzo, A.; Tolosa, E.; Santamarìa, J.; Gizewski, E.; Schocke, M.; Skalla, E.; Kremser, C.; Poewe, W. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol., 2016, 79(6), 1026-1030. doi: 10.1002/ana.24646 PMID: 27016314
  181. Sun, J.; Lai, Z.; Ma, J.; Gao, L.; Chen, M.; Chen, J.; Fang, J.; Fan, Y.; Bao, Y.; Zhang, D.; Chan, P.; Yang, Q.; Ye, C.; Wu, T.; Ma, T. Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder. Mov. Disord., 2020, 35(3), 478-485. doi: 10.1002/mds.27929 PMID: 31846123
  182. Zhang, X.; Chai, C.; Ghassaban, K.; Ye, J.; Huang, Y.; Zhang, T.; Wu, W.; Zhu, J.; Zhang, X.; Haacke, E.M.; Wang, Z.; Xue, R.; Xia, S. Assessing brain iron and volume of subcortical nuclei in idiopathic rapid eye movement sleep behavior disorder. Sleep, 2021, 44(10), zsab131. doi: 10.1093/sleep/zsab131 PMID: 34015127
  183. Lee, J.H.; Han, Y.H.; Cho, J.W.; Lee, J.S.; Lee, S.J.; Kim, D.J.; Kim, T.H.; Kang, B.M.; Kim, T.H.; Mun, C.W. Evaluation of brain iron content in idiopathic REM sleep behavior disorder using quantitative magnetic resonance imaging. Parkinsonism Relat. Disord., 2014, 20(7), 776-778. doi: 10.1016/j.parkreldis.2014.03.023 PMID: 24731528
  184. Pyatigorskaya, N.; Gaurav, R.; Arnaldi, D.; Leu-Semenescu, S.; Yahia-Cherif, L.; Valabregue, R.; Vidailhet, M.; Arnulf, I.; Lehéricy, S. Magnetic resonance imaging biomarkers to assess substantia nigra damage in idiopathic rapid eye movement sleep behavior disorder. Sleep, 2017, 40(11) doi: 10.1093/sleep/zsx149 PMID: 28958075
  185. Sulzer, D.; Cassidy, C.; Horga, G.; Kang, U.J.; Fahn, S.; Casella, L.; Pezzoli, G.; Langley, J.; Hu, X.P.; Zucca, F.A.; Isaias, I.U.; Zecca, L. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. NPJ Parkinsons Dis., 2018, 4(1), 11. doi: 10.1038/s41531-018-0047-3 PMID: 29644335
  186. Zhang, W.; Phillips, K.; Wielgus, A.R.; Liu, J.; Albertini, A.; Zucca, F.A.; Faust, R.; Qian, S.Y.; Miller, D.S.; Chignell, C.F.; Wilson, B.; Jackson-Lewis, V.; Przedborski, S.; Joset, D.; Loike, J.; Hong, J.S.; Sulzer, D.; Zecca, L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: Implications for progression of Parkinson’s disease. Neurotox. Res., 2011, 19(1), 63-72. doi: 10.1007/s12640-009-9140-z PMID: 19957214
  187. Zecca, L.; Fariello, R.; Riederer, P.; Sulzer, D.; Gatti, A.; Tampellini, D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett., 2002, 510(3), 216-220. doi: 10.1016/S0014-5793(01)03269-0 PMID: 11801257
  188. Zecca, L.; Stroppolo, A.; Gatti, A.; Tampellini, D.; Toscani, M.; Gallorini, M.; Giaveri, G.; Arosio, P.; Santambrogio, P.; Fariello, R.G.; Karatekin, E.; Kleinman, M.H.; Turro, N.; Hornykiewicz, O.; Zucca, F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. USA, 2004, 101(26), 9843-9848. doi: 10.1073/pnas.0403495101 PMID: 15210960
  189. Ohtsuka, C.; Sasaki, M.; Konno, K.; Kato, K.; Takahashi, J.; Yamashita, F.; Terayama, Y. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat. Disord., 2014, 20(7), 755-760. doi: 10.1016/j.parkreldis.2014.04.005 PMID: 24768616
  190. Biondetti, E.; Gaurav, R.; Yahia-Cherif, L.; Mangone, G.; Pyatigorskaya, N.; Valabrègue, R.; Ewenczyk, C.; Hutchison, M.; François, C.; Arnulf, I.; Corvol, J.C.; Vidailhet, M.; Lehéricy, S. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson’s disease. Brain, 2020, 143(9), 2757-2770. doi: 10.1093/brain/awaa216 PMID: 32856056
  191. Ogisu, K.; Kudo, K.; Sasaki, M.; Sakushima, K.; Yabe, I.; Sasaki, H.; Terae, S.; Nakanishi, M.; Shirato, H. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology, 2013, 55(6), 719-724. doi: 10.1007/s00234-013-1171-8 PMID: 23525598
  192. Ohtsuka, C.; Sasaki, M.; Konno, K.; Koide, M.; Kato, K.; Takahashi, J.; Takahashi, S.; Kudo, K.; Yamashita, F.; Terayama, Y. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci. Lett., 2013, 541, 93-98. doi: 10.1016/j.neulet.2013.02.012 PMID: 23428505
  193. Pyatigorskaya, N.; Magnin, B.; Mongin, M.; Yahia-Cherif, L.; Valabregue, R.; Arnaldi, D.; Ewenczyk, C.; Poupon, C.; Vidailhet, M.; Lehéricy, S. Comparative STudy of MRI biomarkers in the substantia nigra to discriminate idiopathic Parkinson disease. AJNR Am. J. Neuroradiol., 2018, 39(8), 1460-1467. doi: 10.3174/ajnr.A5702 PMID: 29954816
  194. Kitao, S.; Matsusue, E.; Fujii, S.; Miyoshi, F.; Kaminou, T.; Kato, S.; Ito, H.; Ogawa, T. Correlation between pathology and neuromelanin MR imaging in Parkinson’s disease and dementia with Lewy bodies. Neuroradiology, 2013, 55(8), 947-953. doi: 10.1007/s00234-013-1199-9 PMID: 23673875
  195. Ehrminger, M.; Latimier, A.; Pyatigorskaya, N.; Garcia-Lorenzo, D.; Leu-Semenescu, S.; Vidailhet, M.; Lehericy, S.; Arnulf, I. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain, 2016, 139(4), 1180-1188. doi: 10.1093/brain/aww006 PMID: 26920675
  196. Luppi, P.H.; Clément, O.; Valencia Garcia, S.; Brischoux, F.; Fort, P. New aspects in the pathophysiology of rapid eye movement sleep behavior disorder: the potential role of glutamate, gamma-aminobutyric acid, and glycine. Sleep Med., 2013, 14(8), 714-718. doi: 10.1016/j.sleep.2013.02.004 PMID: 23790501
  197. Wang, X.; Zhang, Y.; Zhu, C.; Li, G.; Kang, J.; Chen, F.; Yang, L. The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: Meta-analysis. Neurol. Sci., 2019, 40(12), 2479-2489. doi: 10.1007/s10072-019-04014-y PMID: 31392640
  198. Scherfler, C.; Frauscher, B.; Schocke, M.; Iranzo, A.; Gschliesser, V.; Seppi, K.; Santamaria, J.; Tolosa, E.; Högl, B.; Poewe, W.; Group, S. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion-tensor imaging and voxel-based morphometry study. Ann. Neurol., 2011, 69(2), 400-407. doi: 10.1002/ana.22245 PMID: 21387382
  199. Unger, M.M.; Belke, M.; Menzler, K.; Heverhagen, J.T.; Keil, B.; Stiasny-Kolster, K.; Rosenow, F.; Diederich, N.J.; Mayer, G.; Möller, J.C.; Oertel, W.H.; Knake, S. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep, 2010, 33(6), 767-773. doi: 10.1093/sleep/33.6.767 PMID: 20550017
  200. Holtbernd, F.; Romanzetti, S.; Oertel, W.H.; Knake, S.; Sittig, E.; Heidbreder, A.; Maier, A.; Krahe, J.; Wojtala, J.; Dogan, I.; Schulz, J.B.; Schiefer, J.; Janzen, A.; Reetz, K. Convergent patterns of structural brain changes in rapid eye movement sleep behavior disorder and Parkinson’s disease on behalf of the German rapid eye movement sleep behavior disorder study group. Sleep, 2021, 44(3), zsaa199. doi: 10.1093/sleep/zsaa199 PMID: 32974664
  201. Ellmore, T.M.; Hood, A.J.; Castriotta, R.J.; Stimming, E.F.; Bick, R.J.; Schiess, M.C. Reduced volume of the putamen in REM sleep behavior disorder patients. Parkinsonism Relat. Disord., 2010, 16(10), 645-649. doi: 10.1016/j.parkreldis.2010.08.014 PMID: 20846895
  202. Hanyu, H.; Inoue, Y.; Sakurai, H.; Kanetaka, H.; Nakamura, M.; Miyamoto, T.; Sasai, T.; Iwamoto, T. Voxel-based magnetic resonance imaging study of structural brain changes in patients with idiopathic REM sleep behavior disorder. Parkinsonism Relat. Disord., 2012, 18(2), 136-139. doi: 10.1016/j.parkreldis.2011.08.023 PMID: 21924943
  203. Rahayel, S.; Montplaisir, J.; Monchi, O.; Bedetti, C.; Postuma, R.B.; Brambati, S.; Carrier, J.; Joubert, S.; Latreille, V.; Jubault, T.; Gagnon, J.F. Patterns of cortical thinning in idiopathic rapid eye movement sleep behavior disorder. Mov. Disord., 2015, 30(5), 680-687. doi: 10.1002/mds.25820 PMID: 24676967
  204. Rahayel, S.; Postuma, R.B.; Montplaisir, J.; Bedetti, C.; Brambati, S.; Carrier, J.; Monchi, O.; Bourgouin, P.A.; Gaubert, M.; Gagnon, J.F. Abnormal gray matter shape, thickness, and volume in the motor cortico-subcortical loop in idiopathic rapid eye movement sleep behavior disorder: association with clinical and motor features. Cereb. Cortex, 2018, 28(2), 658-671. doi: 10.1093/cercor/bhx137 PMID: 28591814
  205. Rahayel, S.; Postuma, R.B.; Montplaisir, J.; Génier Marchand, D.; Escudier, F.; Gaubert, M.; Bourgouin, P.A.; Carrier, J.; Monchi, O.; Joubert, S.; Blanc, F.; Gagnon, J.F. Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorder. Neurology, 2018, 90(20), e1759-e1770. doi: 10.1212/WNL.0000000000005523 PMID: 29669906
  206. Campabadal, A.; Segura, B.; Junque, C.; Serradell, M.; Abos, A.; Uribe, C.; Baggio, H.C.; Gaig, C.; Santamaria, J.; Compta, Y.; Bargallo, N.; Iranzo, A. Cortical gray matter and hippocampal atrophy in idiopathic rapid eye movement sleep behavior disorder. Front. Neurol., 2019, 10, 312. doi: 10.3389/fneur.2019.00312 PMID: 31024418
  207. Li, G.; Chen, Z.; Zhou, L.; Zhao, A.; Niu, M.; Li, Y.; Luo, N.; Kang, W.; Liu, J. Altered structure and functional connectivity of the central autonomic network in idiopathic rapid eye movement sleep behaviour disorder. J. Sleep Res., 2021, 30(3), e13136. doi: 10.1111/jsr.13136 PMID: 32608031
  208. Chen, M.; Li, Y.; Chen, J.; Gao, L.; Sun, J.; Gu, Z.; Wu, T.; Chan, P. Structural and functional brain alterations in patients with idiopathic rapid eye movement sleep behavior disorder. J. Neuroradiol., 2022, 4(1), 66-72. PMID: 32540338
  209. Pereira, J.B.; Weintraub, D.; Chahine, L.; Aarsland, D.; Hansson, O.; Westman, E. Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. NPJ Parkinsons Dis., 2019, 5(1), 7. doi: 10.1038/s41531-019-0079-3 PMID: 31069252
  210. Campabadal, A.; Inguanzo, A.; Segura, B.; Serradell, M.; Abos, A.; Uribe, C.; Gaig, C.; Santamaria, J.; Compta, Y.; Bargallo, N.; Junque, C.; Iranzo, A. Cortical gray matter progression in idiopathic REM sleep behavior disorder and its relation to cognitive decline. Neuroimage Clin., 2020, 28, 102421. doi: 10.1016/j.nicl.2020.102421 PMID: 32957013
  211. Campabadal, A.; Abos, A.; Segura, B.; Serradell, M.; Uribe, C.; Baggio, H.C.; Gaig, C.; Santamaria, J.; Compta, Y.; Bargallo, N.; Junque, C.; Iranzo, A. Disruption of posterior brain functional connectivity and its relation to cognitive impairment in idiopathic REM sleep behavior disorder. Neuroimage Clin., 2020, 25, 102138. doi: 10.1016/j.nicl.2019.102138 PMID: 31911344
  212. Ellmore, T.M.; Castriotta, R.J.; Hendley, K.L.; Aalbers, B.M.; Furr-Stimming, E.; Hood, A.J.; Suescun, J.; Beurlot, M.R.; Hendley, R.T.; Schiess, M.C. Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep, 2013, 36(12), 1885-1892. doi: 10.5665/sleep.3222 PMID: 24293763
  213. Rolinski, M.; Griffanti, L.; Piccini, P.; Roussakis, A.A.; Szewczyk-Krolikowski, K.; Menke, R.A.; Quinnell, T.; Zaiwalla, Z.; Klein, J.C.; Mackay, C.E.; Hu, M.T.M. Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson’s disease. Brain, 2016, 139(8), 2224-2234. doi: 10.1093/brain/aww124 PMID: 27297241
  214. Byun, J.I.; Kim, H.W.; Kang, H.; Cha, K.S.; Sunwoo, J.S.; Shin, J.W.; Moon, J.; Lee, S.T.; Jung, K.H.; Chu, K.; Kim, M.; Shin, W.C.; Lee, D.S.; Schenck, C.H.; Lee, S.K.; Jung, K.Y. Altered resting-state thalamo-occipital functional connectivity is associated with cognition in isolated rapid eye movement sleep behavior disorder. Sleep Med., 2020, 69, 198-203. doi: 10.1016/j.sleep.2020.01.010 PMID: 32135454
  215. Li, G.; Zhou, L.; Chen, Z.; Luo, N.; Niu, M.; Li, Y.; Kang, W.; Liu, J. Dynamic functional connectivity impairments in idiopathic rapid eye movement sleep behavior disorder. Parkinsonism Relat. Disord., 2020, 79, 11-17. doi: 10.1016/j.parkreldis.2020.08.003 PMID: 32858487
  216. Chen, Y.; Fan, C.; Yang, W.; Nie, K.; Wu, X.; Yang, Y.; Yang, Y.; Wang, L.; Zhang, Y.; Huang, B. Cortical hypoperfusion in patients with idiopathic rapid eye movement sleep behavior disorder detected with arterial spin-labeled perfusion MRI. Neurol. Sci., 2020, 41(4), 809-815. doi: 10.1007/s10072-019-04118-5 PMID: 31792718
  217. Brück, A.; Aalto, S.; Rauhala, E.; Bergman, J.; Marttila, R.; Rinne, J.O. A follow-up study on 6-18Ffluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov. Disord., 2009, 24(7), 1009-1015. doi: 10.1002/mds.22484 PMID: 19260097
  218. Nandhagopal, R.; Kuramoto, L.; Schulzer, M.; Mak, E.; Cragg, J.; McKenzie, J.; McCormick, S.; Ruth, T.J.; Sossi, V.; de la Fuente-Fernandez, R.; Stoessl, A.J. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain, 2011, 134(11), 3290-3298. doi: 10.1093/brain/awr233 PMID: 22075521
  219. Jakobson Mo, S.; Linder, J.; Forsgren, L.; Holmberg, H.; Larsson, A.; Riklund, K. Pre- and postsynaptic dopamine SPECT in idiopathic Parkinsonian diseases: a follow-up study. BioMed Res. Int., 2013, 2013, 1-14. doi: 10.1155/2013/143532 PMID: 24163811
  220. Marek, K.; Innis, R.; van Dyck, C.; Fussell, B.; Early, M.; Eberly, S.; Oakes, D.; Seibyl, J. 123I -CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology, 2001, 57(11), 2089-2094. doi: 10.1212/WNL.57.11.2089 PMID: 11739831
  221. Pirker, W.; Djamshidian, S.; Asenbaum, S.; Gerschlager, W.; Tribl, G.; Hoffmann, M.; Brücke, T. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: A longitudinal β-CIT SPECT study. Mov. Disord., 2002, 17(1), 45-53. doi: 10.1002/mds.1265 PMID: 11835438
  222. Nocker, M.; Seppi, K.; Donnemiller, E.; Virgolini, I.; Wenning, G.K.; Poewe, W.; Scherfler, C. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of 123Iβ-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(6), 1012-1020. doi: 10.1007/s00259-012-2100-5 PMID: 22460689
  223. Sakakibara, S.; Hashimoto, R.; Katayama, T.; Kenjyo, M.; Yokokawa, Y.; Saito, Y.; Hirakawa, A.; Ito, M.; Nakamura, T.; Hara, K.; Hashizume, A.; Aiba, I.; Inukai, A.; Katsuno, M. Longitudinal change of DAT SPECT in Parkinson’s Disease and multiple system atrophy. J. Parkinsons Dis., 2020, 10(1), 123-130. doi: 10.3233/JPD-191710 PMID: 31707374
  224. Schwarz, J.; Storch, A.; Koch, W.; Pogarell, O.; Radau, P.E.; Tatsch, K. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. J. Nucl. Med., 2004, 45(10), 1694-1697. PMID: 15471835
  225. Simuni, T.; Siderowf, A.; Lasch, S.; Coffey, C.S.; Caspell-Garcia, C.; Jennings, D.; Tanner, C.M.; Trojanowski, J.Q.; Shaw, L.M.; Seibyl, J.; Schuff, N.; Singleton, A.; Kieburtz, K.; Toga, A.W.; Mollenhauer, B.; Galasko, D.; Chahine, L.M.; Weintraub, D.; Foroud, T.; Tosun, D.; Poston, K.; Arnedo, V.; Frasier, M.; Sherer, T.; Chowdhury, S.; Marek, K. Longitudinal change of clinical and biological measures in early Parkinson’s disease: Parkinson’s progression markers initiative cohort. Mov. Disord., 2018, 33(5), 771-782. doi: 10.1002/mds.27361 PMID: 29572948
  226. Huang, C.; Tang, C.; Feigin, A.; Lesser, M.; Ma, Y.; Pourfar, M.; Dhawan, V.; Eidelberg, D. Changes in network activity with the progression of Parkinson’s disease. Brain, 2007, 130(7), 1834-1846. doi: 10.1093/brain/awm086 PMID: 17470495
  227. Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A.; Lang, A.; Olanow, C.W.; Tanner, C.; Marek, K. Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med., 2004, 351(24), 2498-2508. doi: 10.1056/NEJMoa033447 PMID: 15590952
  228. Merchant, K.M.; Cedarbaum, J.M.; Brundin, P.; Dave, K.D.; Eberling, J.; Espay, A.J.; Hutten, S.J.; Javidnia, M.; Luthman, J.; Maetzler, W.; Menalled, L.; Reimer, A.N.; Stoessl, A.J.; Weiner, D.M. The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group. A proposed roadmap for Parkinson’s disease proof of concept clinical trials investigating compounds targeting alpha-synuclein. J. Parkinsons Dis., 2019, 9(1), 31-61. doi: 10.3233/JPD-181471 PMID: 30400107
  229. Lyoo, C.H.; Jeong, Y.; Ryu, Y.H.; Lee, S.Y.; Song, T.J.; Lee, J.H.; Rinne, J.O.; Lee, M.S. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain, 2008, 131(2), 438-446. doi: 10.1093/brain/awm328 PMID: 18178568
  230. Lee, P.H.; Kim, J.W.; Bang, O.Y.; Ahn, Y.H.; Joo, I.S.; Huh, K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin. Pharmacol. Ther., 2008, 83(5), 723-730. doi: 10.1038/sj.clpt.6100386 PMID: 17898702
  231. Korat, Š.; Bidesi, N.S.R.; Bonanno, F.; Di Nanni, A.; Hoàng, A.N.N.; Herfert, K.; Maurer, A.; Battisti, U.M.; Bowden, G.D.; Thonon, D.; Vugts, D.; Windhorst, A.D.; Herth, M.M. Alpha-synuclein PET tracer development—an overview about current efforts. Pharmaceuticals, 2021, 14(9), 847. doi: 10.3390/ph14090847 PMID: 34577548
  232. Strohäker, T.; Jung, B.C.; Liou, S.H.; Fernandez, C.O.; Riedel, D.; Becker, S.; Halliday, G.M.; Bennati, M.; Kim, W.S.; Lee, S.J.; Zweckstetter, M. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nat. Commun., 2019, 10(1), 5535. doi: 10.1038/s41467-019-13564-w PMID: 31797870
  233. Van der Perren, A.; Gelders, G.; Fenyi, A.; Bousset, L.; Brito, F.; Peelaerts, W.; Van den Haute, C.; Gentleman, S.; Melki, R.; Baekelandt, V. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol., 2020, 139(6), 977-1000. doi: 10.1007/s00401-020-02157-3 PMID: 32356200
  234. Kuebler, L.; Buss, S.; Leonov, A.; Ryazanov, S.; Schmidt, F.; Maurer, A.; Weckbecker, D.; Landau, A.M.; Lillethorup, T.P.; Bleher, D.; Saw, R.S.; Pichler, B.J.; Griesinger, C.; Giese, A.; Herfert, K. 11CMODAG-001—towards a PET tracer targeting α-synuclein aggregates. Eur. J. Nucl. Med. Mol. Imaging, 2021, 48(6), 1759-1772. doi: 10.1007/s00259-020-05133-x PMID: 33369690
  235. Deeg, A.A.; Reiner, A.M.; Schmidt, F.; Schueder, F.; Ryazanov, S.; Ruf, V.C.; Giller, K.; Becker, S.; Leonov, A.; Griesinger, C.; Giese, A.; Zinth, W. Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates. Biochim. Biophys. Acta, Gen. Subj., 2015, 1850(9), 1884-1890. doi: 10.1016/j.bbagen.2015.05.021 PMID: 26028294
  236. Heras-Garvin, A.; Weckbecker, D.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G.K.; Stefanova, N. Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov. Disord., 2019, 34(2), 255-263. doi: 10.1002/mds.27562 PMID: 30452793
  237. Frey, K.A. Molecular imaging of extrapyramidal movement disorders with dementia: The 4R tauopathies. Semin. Nucl. Med., 2021, 51(3), 275-285. doi: 10.1053/j.semnuclmed.2020.12.003 PMID: 33431202
  238. Whitwell, J.L.; Tosakulwong, N.; Schwarz, C.G.; Botha, H.; Senjem, M.L.; Spychalla, A.J.; Ahlskog, J.E.; Knopman, D.S.; Petersen, R.C.; Jack, C.R., Jr; Lowe, V.J.; Josephs, K.A. MRI Outperforms 18FAV‐1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov. Disord., 2019, 34(1), 105-113. doi: 10.1002/mds.27546 PMID: 30468693
  239. Lowe, V.J.; Curran, G.; Fang, P.; Liesinger, A.M.; Josephs, K.A.; Parisi, J.E.; Kantarci, K.; Boeve, B.F.; Pandey, M.K.; Bruinsma, T.; Knopman, D.S.; Jones, D.T.; Petrucelli, L.; Cook, C.N.; Graff-Radford, N.R.; Dickson, D.W.; Petersen, R.C.; Jack, C.R., Jr; Murray, M.E. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol. Commun., 2016, 4(1), 58. doi: 10.1186/s40478-016-0315-6 PMID: 27296779
  240. Okamura, N.; Harada, R.; Ishiki, A.; Kikuchi, A.; Nakamura, T.; Kudo, Y. The development and validation of tau PET tracers: Current status and future directions. Clin. Transl. Imaging, 2018, 6(4), 305-316. doi: 10.1007/s40336-018-0290-y PMID: 30148121
  241. Coakeley, S.; Cho, S.S.; Koshimori, Y.; Rusjan, P.; Ghadery, C.; Kim, J.; Lang, A.E.; Houle, S.; Strafella, A.P. 18FAV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Struct. Funct., 2018, 223(2), 589-595. doi: 10.1007/s00429-017-1507-y PMID: 28884232
  242. Hansen, A.K.; Knudsen, K.; Lillethorup, T.P.; Landau, A.M.; Parbo, P.; Fedorova, T.; Audrain, H.; Bender, D.; Østergaard, K.; Brooks, D.J.; Borghammer, P. In vivo imaging of neuromelanin in Parkinson’s disease using 18 F-AV-1451 PET. Brain, 2016, 139(7), 2039-2049. doi: 10.1093/brain/aww098 PMID: 27190023
  243. Goedert, M.; Spillantini, M.G.; Cairns, N.J.; Crowther, R.A. Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron, 1992, 8(1), 159-168. doi: 10.1016/0896-6273(92)90117-V PMID: 1530909
  244. Flament, S.; Delacourte, A.; Verny, M.; Hauw, J.J.; Javoy-Agid, F. Abnormal Tau proteins in progressive supranuclear palsy. Acta Neuropathol., 1991, 81(6), 591-596. doi: 10.1007/BF00296367 PMID: 1831952
  245. Ksiezak-Reding, H.; Morgan, K.; Mattiace, L.A.; Davies, P.; Liu, W.K.; Yen, S.H.; Weidenheim, K.; Dickson, D.W. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am. J. Pathol., 1994, 145(6), 1496-1508. PMID: 7992852
  246. Ono, M.; Sahara, N.; Kumata, K.; Ji, B.; Ni, R.; Koga, S.; Dickson, D.W.; Trojanowski, J.Q.; Lee, V.M.Y.; Yoshida, M.; Hozumi, I.; Yoshiyama, Y.; van Swieten, J.C.; Nordberg, A.; Suhara, T.; Zhang, M.R.; Higuchi, M. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain, 2017, 140(3), aww339. doi: 10.1093/brain/aww339 PMID: 28087578
  247. Gaurav, R.; Yahia-Cherif, L.; Pyatigorskaya, N.; Mangone, G.; Biondetti, E.; Valabrègue, R.; Ewenczyk, C.; Hutchison, R.M.; Cedarbaum, J.M.; Corvol, J.C.; Vidailhet, M.; Lehéricy, S. Longitudinal changes in neuromelanin MRI Signal in Parkinson’s Disease: A progression marker. Mov. Disord., 2021, 36(7), 1592-1602. doi: 10.1002/mds.28531 PMID: 33751655
  248. Matsuura, K.; Maeda, M.; Tabei, K.; Umino, M.; Kajikawa, H.; Satoh, M.; Kida, H.; Tomimoto, H. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci. Lett., 2016, 633, 112-117. doi: 10.1016/j.neulet.2016.09.011 PMID: 27619539
  249. Arpin, D.J.; Mitchell, T.; Archer, D.B.; Burciu, R.G.; Chu, W.T.; Gao, H.; Guttuso, T.; Hess, C.W.; Lai, S.; Malaty, I.A.; McFarland, N.R.; Pasternak, O.; Price, C.C.; Shukla, A.W.; Wu, S.S.; Okun, M.S.; Vaillancourt, D.E. Diffusion magnetic resonance imaging detects progression in Parkinson’s disease: A placebo-controlled trial of rasagiline. Mov. Disord., 2022, 37(2), 325-333. PMID: 34724257
  250. Vaillancourt, D.E.; Mitchell, T. Parkinson’s disease progression in the substantia nigra: Location, location, location. Brain, 2020, 143(9), 2628-2630. doi: 10.1093/brain/awaa252 PMID: 32947614
  251. Chung, J.W.; Burciu, R.G.; Ofori, E.; Shukla, P.; Okun, M.S.; Hess, C.W.; Vaillancourt, D.E. Parkinson’s disease diffusion MRI is not affected by acute antiparkinsonian medication. Neuroimage Clin., 2017, 14, 417-421. doi: 10.1016/j.nicl.2017.02.012 PMID: 28275542
  252. Caso, F.; Agosta, F.; Ječmenica-Lukić, M.; Petrović, I.; Meani, A.; Kostic, V.S.; Filippi, M. Progression of white matter damage in progressive supranuclear palsy with predominant parkinsonism. Parkinsonism Relat. Disord., 2018, 49, 95-99. doi: 10.1016/j.parkreldis.2018.01.001 PMID: 29336906
  253. Reginold, W.; Lang, A.E.; Marras, C.; Heyn, C.; Alharbi, M.; Mikulis, D.J. Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat. Disord., 2014, 20(2), 222-225. doi: 10.1016/j.parkreldis.2013.10.002 PMID: 24239142
  254. Zhang, Y.; Walter, R.; Ng, P.; Luong, P.N.; Dutt, S.; Heuer, H.; Rojas-Rodriguez, J.C.; Tsai, R.; Litvan, I.; Dickerson, B.C.; Tartaglia, M.C.; Rabinovici, G.; Miller, B.L.; Rosen, H.J.; Schuff, N.; Boxer, A.L. Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: A longitudinal diffusion tensor imaging study. PLoS One, 2016, 11(6), e0157218. doi: 10.1371/journal.pone.0157218 PMID: 27310132
  255. Hanganu, A.; Bedetti, C.; Degroot, C.; Mejia-Constain, B.; Lafontaine, A.L.; Soland, V.; Chouinard, S.; Bruneau, M.A.; Mellah, S.; Belleville, S.; Monchi, O. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain, 2014, 137(4), 1120-1129. doi: 10.1093/brain/awu036 PMID: 24613932
  256. Mak, E.; Su, L.; Williams, G.B.; Firbank, M.J.; Lawson, R.A.; Yarnall, A.J.; Duncan, G.W.; Owen, A.M.; Khoo, T.K.; Brooks, D.J.; Rowe, J.B.; Barker, R.A.; Burn, D.J.; O’Brien, J.T. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain, 2015, 138(10), 2974-2986. doi: 10.1093/brain/awv211 PMID: 26173861
  257. Ibarretxe-Bilbao, N.; Junque, C.; Segura, B.; Baggio, H.C.; Marti, M.J.; Valldeoriola, F.; Bargallo, N.; Tolosa, E. Progression of cortical thinning in early Parkinson’s disease. Mov. Disord., 2012, 27(14), 1746-1753. doi: 10.1002/mds.25240 PMID: 23124622
  258. Yau, Y.; Zeighami, Y.; Baker, T.E.; Larcher, K.; Vainik, U.; Dadar, M.; Fonov, V.S.; Hagmann, P.; Griffa, A.; Mišić, B.; Collins, D.L.; Dagher, A. Network connectivity determines cortical thinning in early Parkinson’s disease progression. Nat. Commun., 2018, 9(1), 12. doi: 10.1038/s41467-017-02416-0 PMID: 29295991
  259. Campabadal, A.; Uribe, C.; Segura, B.; Baggio, H.C.; Abos, A.; Garcia-Diaz, A.I.; Marti, M.J.; Valldeoriola, F.; Compta, Y.; Bargallo, N.; Junque, C. Brain correlates of progressive olfactory loss in Parkinson’s disease. Parkinsonism Relat. Disord., 2017, 41, 44-50. doi: 10.1016/j.parkreldis.2017.05.005 PMID: 28522171
  260. Sterling, N.W.; Wang, M.; Zhang, L.; Lee, E.Y.; Du, G.; Lewis, M.M.; Styner, M.; Huang, X. Stage-dependent loss of cortical gyrification as Parkinson disease "unfolds". Neurology, 2016, 86(12), 1143-1151. doi: 10.1212/WNL.0000000000002492 PMID: 26888982
  261. Dutt, S.; Binney, R.J.; Heuer, H.W.; Luong, P.; Attygalle, S.; Bhatt, P.; Marx, G.A.; Elofson, J.; Tartaglia, M.C.; Litvan, I.; McGinnis, S.M.; Dickerson, B.C.; Kornak, J.; Waltzman, D.; Voltarelli, L.; Schuff, N.; Rabinovici, G.D.; Kramer, J.H.; Jack, C.R., Jr; Miller, B.L.; Rosen, H.J.; Boxer, A.L. AL-108-231 investigators. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87(19), 2016-2025. doi: 10.1212/WNL.0000000000003305 PMID: 27742814
  262. Südmeyer, M.; Pieperhoff, P.; Ferrea, S.; Krause, H.; Groiss, S.J.; Elben, S.; Wojtecki, L.; Zilles, K.; Amunts, K.; Schnitzler, A. Longitudinal deformation-based morphometry reveals spatio-temporal dynamics of brain volume changes in patients with corticobasal syndrome. PLoS One, 2012, 7(7), e41873. doi: 10.1371/journal.pone.0041873 PMID: 22848644
  263. Agosta, F.; Caso, F.; Ječmenica-Lukić, M.; Petrović, I.N.; Valsasina, P.; Meani, A.; Copetti, M.; Kostić, V.S.; Filippi, M. Tracking brain damage in progressive supranuclear palsy: A longitudinal MRI study. J. Neurol. Neurosurg. Psychiatry, 2018, 89(7), 696-701. doi: 10.1136/jnnp-2017-317443 PMID: 29348302
  264. Paviour, D.C.; Price, S.L.; Jahanshahi, M.; Lees, A.J.; Fox, N.C. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain, 2006, 129(4), 1040-1049. doi: 10.1093/brain/awl021 PMID: 16455792
  265. Minnerop, M.; Lüders, E.; Specht, K.; Ruhlmann, J.; Schimke, N.; Thompson, P.M.; Chou, Y.Y.; Toga, A.W.; Abele, M.; Wüllner, U.; Klockgether, T. Callosal tissue loss in multiple system atrophy-A one-year follow-up study. Mov. Disord., 2010, 25(15), 2613-2620. doi: 10.1002/mds.23318 PMID: 20623690
  266. Quattrone, A.; Morelli, M.; Quattrone, A.; Vescio, B.; Nigro, S.; Arabia, G.; Nisticò, R.; Novellino, F.; Salsone, M.; Arcuri, P.; Luca, A.; Mazzuca, A.; Alessio, C.; Rocca, F.; Caracciolo, M. Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study. Parkinsonism Relat. Disord., 2020, 72, 1-6. doi: 10.1016/j.parkreldis.2020.01.019 PMID: 32036297
  267. Nigro, S.; Morelli, M.; Arabia, G.; Nisticò, R.; Novellino, F.; Salsone, M.; Rocca, F.; Quattrone, A. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease? Parkinsonism Relat. Disord., 2017, 41, 31-36. doi: 10.1016/j.parkreldis.2017.05.002 PMID: 28487107

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers